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Abstract: Background & Aims:  Atherosclerosis is characterized by an inflammatory disease
linked to excessive lipid accumulation in the artery wall. The Notch signalling pathway
has been shown to play a key regulatory role in the regulation of inflammation.
Recently,  in vitro  and pre-clinical studies have shown that apolipoprotein A-I binding
protein (AIBP) regulates cholesterol metabolism(SREBP) and NOTCH signalling
(haematopoiesis) and may be protective against atherosclerosis, but the evidence in
humans is scarce.
Methods:  Weevaluated the  APOA1BP-SREBF-NOTCH  axis in association with
atherosclerosis in two well-characterized cohorts of morbidly obese patients (  n  = 78)
within the FLORINASH study, including liver transcriptomics,  1  H-NMR plasma
metabolomics, high-resolution ultrasonography evaluating carotid intima-media
thickness (cIMT), and haematological parameters.
Results:  The liver expression levels of  APOA1BP  were associated with lower cIMT
and leukocyte counts, a better plasma lipid profile and higher circulating levels of
metabolites associated with lower risk of atherosclerosis (glycine, histidine and
asparagine). Conversely, liver  SREBF  and  NOTCH  mRNAs were positively
associated with atherosclerosis, liver steatosis, an unfavourable lipid profile, higher
leukocytes and increased levels of metabolites linked to inflammation and CVD such
as branched-chain amino acids and glycoproteins.  APOA1BP  and NOTCH signalling
also had a strong association, as revealed by the negative correlations among
APOA1BP  expression levels and those of all NOTCH receptors and jagged ligands.
Conclusions:  We hereprovide the first evidence in human liverof the putative
APOA1BP  -  SREBF-NOTCH  axis signalling pathway and its association with
atherosclerosis and inflammation.
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Background & Aims: Atherosclerosis is characterized by an inflammatory disease 56 
linked to excessive lipid accumulation in the artery wall. The Notch signalling pathway 57 
has been shown to play a key regulatory role in the regulation of inflammation. Recently, 58 
in vitro and pre-clinical studies have shown that apolipoprotein A-I binding protein 59 
(AIBP) regulates cholesterol metabolism (SREBP) and NOTCH signalling 60 
(haematopoiesis) and may be protective against atherosclerosis, but the evidence in 61 
humans is scarce. 62 
Methods: We evaluated the APOA1BP-SREBF-NOTCH axis in association with 63 
atherosclerosis in two well-characterized cohorts of morbidly obese patients (n = 78) 64 
within the FLORINASH study, including liver transcriptomics, 1H-NMR plasma 65 
metabolomics, high-resolution ultrasonography evaluating carotid intima-media 66 
thickness (cIMT), and haematological parameters. 67 
Results: The liver expression levels of APOA1BP were associated with lower cIMT and 68 
leukocyte counts, a better plasma lipid profile and higher circulating levels of metabolites 69 
associated with lower risk of atherosclerosis (glycine, histidine and asparagine). 70 
Conversely, liver SREBF and NOTCH mRNAs were positively associated with 71 
atherosclerosis, liver steatosis, an unfavourable lipid profile, higher leukocytes and 72 
increased levels of metabolites linked to inflammation and CVD such as branched-chain 73 
amino acids and glycoproteins. APOA1BP and NOTCH signalling also had a strong 74 
association, as revealed by the negative correlations among APOA1BP expression levels 75 
and those of all NOTCH receptors and jagged ligands. 76 
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Conclusions: We here provide the first evidence in human liver of the putative 77 
APOA1BP-SREBF-NOTCH axis signalling pathway and its association with 78 
atherosclerosis and inflammation.  79 
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Atherosclerosis is the major cause of cardiovascular disease (CVD), the leading cause of 80 
death worldwide. Several studies have shown the anti-atherogenic potential of the high-81 
density lipoprotein (HDL)-mediated reverse cholesterol transport (RCT) [1]. In this 82 
process, excess cholesterol is transported from macrophages and peripheral tissues back 83 
to the liver for excretion. A critical part of RCT is cholesterol efflux, in which intracellular 84 
cholesterol is released and collected by apolipoprotein A1 (APOA1), the major 85 
component of HDL [2]. In fact, the cholesterol efflux potential of HDL is a better 86 
predictor of CVD than circulating HDL levels [3]. The ATP-binding cassette transporter 87 
A1 (ABCA1), a cell-membrane protein, is the major transporter that mediates this 88 
assembly of cholesterol with APOA1, which is the rate-limiting step in the formation of 89 
nascent HDLs.  90 
The APOA1 binding protein (AIBP), encoded by APOA1BP in humans, is a secreted 91 
protein physically associated with APOA1 [4] that enhances cholesterol efflux in vitro 92 
from macrophages [5] and endothelial cells [6] in the presence of APOA1 or HDL, partly 93 
by facilitating apoA1 binding to ABCA1 and preventing ABCA1 degradation [5]. 94 
Recently, AIBP has shown to protect against atherosclerosis in vivo in Apoe-/- and Ldlr-/- 95 
mice by promoting cholesterol efflux and ameliorating inflammation [7,8]. Human 96 
APOA1BP mRNA is ubiquitously expressed and abundant in most human secretory 97 
organs, with the highest expression in kidney, heart, liver, thyroid gland, adrenal gland, 98 
and testis [4]. It is of note that kidney and liver are the major sites of APOA1 catabolism. 99 
Atherosclerosis is characterized by progressive accumulation of lipids and leukocytes in 100 
the intima layer of the arterial wall. It is considered a chronic inflammation disease with 101 
monocytes/macrophages, the main immune cells of the innate immune response, playing 102 
a major role in all stages of atherosclerosis [9]. Notably, the Notch pathway is well-103 
recognized as a major regulator of cell fate in stem cells and the differentiation of the 104 
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various cell types of the immune system [10]. Recently, the Notch signalling pathway 105 
was shown to play an important role in the onset and progression of atherosclerosis by 106 
promoting inflammation through induction of a pro-inflammatory M1 phenotype in 107 
macrophages, a switch towards a Th-1 like inflammatory phenotype in differentiated 108 
regulatory T cells, and promoting CD8 cytotoxic T cells [11].  109 
Recent evidence suggests a control of hematopoietic progenitor and stem cells (HPSC) 110 
by cholesterol pathways [12], thereby linking haematopoiesis with atherosclerosis. 111 
Interestingly, a connection between AIBP-mediated cholesterol metabolism and Notch 112 
signalling has been described recently. AIBP was shown to regulate Notch signalling 113 
through relocalization of -secretase from lipid to non-lipid rafts in mice [13] and 114 
zebrafish Aibp2-mediated cholesterol efflux was shown to active endothelial Srebp2, 115 
which in turn trans-activates Notch and promotes HSPC emergence. These observations 116 
suggest a role for the AIBP-SREBP-NOTCH axis in atherosclerosis [14]. Although the 117 
bone marrow is the primary site of haematopoiesis in adults, the liver is the main site 118 
during prenatal development and hepatic haematopoiesis is believed to persist into 119 
adulthood [15,16]. 120 
No study has, to date, addressed the potential association between AIBP and Notch 121 
signalling in humans. Here, we studied this connection in two well-characterized cohorts 122 
of morbidly obese patients recruited to the FLORINASH study (17) combining hepatic 123 
transcriptome, plasma metabolome, and carotid intima-media thickness (cIMT) 124 
measures. 125 
  126 
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Subjects and Methods 127 
STUDY POPULATION AND SAMPLE COLLECTION 128 
The study population (n = 78) included two cohorts of morbidly obese patients aged 22 129 
to 61 years old recruited at the Endocrinology Service of the Hospital Universitari de 130 
Girona Dr Josep Trueta (Girona, Spain, n = 32) and at the Center for Atherosclerosis of 131 
Policlinico Tor Vergata University of Rome (Rome, Italy, n = 46), as part of the 132 
FLORINASH study [17]. All subjects gave written informed consent, which was 133 
validated and approved by the ethical committees of the Hospital Universitari Dr Josep 134 
Trueta (Comitè d’Ètica d’Investigació Clínica, approval number 2009 046) and 135 
Policlinico Tor Vergata University of Rome (Comitato Etico Indipendente, approval 136 
number 28-05-2009). Inclusion criteria included Caucasian origin, stable body weight 3 137 
months before the study, free of any infection one month preceding the study and absence 138 
of any systemic disease. Exclusion criteria included presence of liver disease and thyroid 139 
dysfunction, alcohol consumption (> 20 g/day), hepatitis B, drug-induced liver injury, 140 
and dyslipidaemia medication. Plasma samples were obtained during the week before 141 
elective gastric bypass surgery, during which a liver biopsy was sampled. All samples 142 
were stored at −80 °C. Liver samples were collected in RNAlater, fragmented and 143 
immediately flash frozen in liquid nitrogen before storage at −80 °C.  144 
 145 
ANTHROPOMETRIC AND LABORATORY MEASUREMENTS 146 
Blood pressure was measured using a blood pressure monitor (Hem-703C, Omron, 147 
Barcelona, Spain), with the subject seated and after 5 min of rest. Three readings were 148 
obtained and the mean value was used in the analyses. Waist circumference was measured 149 
with a soft tape midway between the lowest rib and the iliac crest. Obesity was considered 150 
as a body mass index (BMI) ≥ 30 kg/m2.  151 
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After 8 h fasting, blood was drawn for the measurement of plasma lipids, glucose and 152 
insulin. Glucose and lipids were determined by standard laboratory methods. Intra-assay 153 
and inter-assay coefficients of variation (CV) were less than 4 %. Serum insulin was 154 
measured in duplicate using a monoclonal immunoradiometric assay (Medgenix 155 
Diagnostics, Fleunes, Belgium). The intra-assay CV was 5.2 % at a concentration of 10 156 
mU/L and 3.4 % at 130 mU/L. The interassay CVs were 6.9 % and 4.5 % at 14 and 89 157 
mU/L, respectively. Glycated haemoglobin (HbA1c) was measured by high-pressure 158 
liquid chromatography using a fully automated glycated haemoglobin analyser system 159 
(Hitachi L-9100; Hitachi, Tokyo, Japan). Insulin resistance was determined by the 160 
homeostasis model assessment of insulin resistance (HOMA-IR). High sensitive C-161 
reactive protein (HsCRP) was determined by ultrasensitive assay (Beckman, Fullerton, 162 
CA), with intra-and inter-assay CVs of 4 %. Serum alanine aminotransferase (ALT) and 163 
aspartate aminotransferase (AST) levels were determined using enzymatic methods. 164 
 165 
LIVER HISTOLOGY 166 
Liver biopsies were analysed by a single pathologist expert in hepatic pathology. For each 167 
liver sample, haematoxylin and eosin, reticulin, and Masson’s trichrome staining were 168 
performed. Hepatic steatosis grade was determined according to the scoring system for 169 
NAFLD and defined as absent (grade 0: <5% steatosis), mild (grade 1: 5-33% steatosis), 170 
moderate (grade 2: >33-66% steatosis) or severe (grade 3: >66% steatosis) [18]. Images 171 
were independently evaluated by two radiologists blinded to clinical and laboratory data. 172 
 173 
  174 
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1H NUCLEAR MAGNETIC RESONANCE (1H-NMR) METABOLIC 175 
PROFILING  176 
Metabolomics analyses have been previously described [17]. Briefly, plasma samples 177 
were thawed at room temperature and 350 µL aliquots were carefully placed in 5-mm 178 
NMR tubes. Then, 150 µL of saline solution (0.9 % NaCl) were added and the mixture 179 
was gently vortexed. Spectroscopic analyses were performed on a Bruker DRX600 180 
spectrometer equipped with either a 5-mm TXI probe operating at 600.13 MHz or a 5-181 
mm BBI probe operating at 600.44 MHz. Spectra were acquired using a water suppressed 182 
Carr-Purcell-Meiboom-Gill using the Bruker program cpmgpr (RD 90º-(-180º-) n-183 
acquire). A RD of 2 s was employed for net magnetization relaxation, during which noise 184 
irradiation was applied in order to suppress the large water proton signal. A number of 185 
loops n = 100 and a spin-echo delay  = 400 µs was used to allow spectral editing through 186 
T2 relaxation and therefore attenuation of broad signals. For each sample, 128 scans were 187 
recorded in 32K data points with a spectral with of 20 ppm. All NMR spectra were 188 
processed using Topspin (Bruker Biospin, UK). Free induction decays were multiplied 189 
by an exponential function corresponding to a line broadening of 0.3 Hz and Fourier 190 
transformed. Spectra were automatically phased, baseline-corrected and referenced to the 191 
anomeric doublet of glucose (5.23 ppm). The spectra were all then imported to MATLAB 192 
and the region around the water resonance (=4.5-5.0) was removed.  193 
 194 
TRANSCRIPTOMICS 195 
Transcriptomic analyses have been previously described [17]. Briefly, RNA from liver 196 
biopsy samples was extracted using standard extraction protocols (TRIzol) by Miltenyi 197 
Biotec as previously reported. RNA quality (gel images, RNA integrity number and 198 
electropherograms) was assessed using an Agilent 2100 Bioanalyzer platform (Agilent 199 
10 
 
Technologies). An RNA integrity number >6 was considered sufficient for gene 200 
expression experiments [19]. One-hundred ng of total RNA were used for linear T7-based 201 
amplification of RNA for each sample. cDNA was prepared by amplification of the RNA 202 
and labelled with Cy3 using the Agilent Low Input Quick Amp Labeling Kit according 203 
to the manufacturer’s instructions. The amounts of cDNA and dye that were incorporated 204 
were measured by an ND-1000 spectrophotometer (NanoDrop Technologies). 205 
Hybridization of the Agilent Whole Human Genome Oligo Microarrays 4 × 44K was 206 
done following the Agilent 60-mer oligo microarray processing protocol using the 207 
Agilent Gene Expression Hybridization Kit. The fluorescence signals of the hybridized 208 
Agilent microarrays were detected using Agilent’s Microarray Scanner after washing 209 
with Agilent Gene Expression Wash Buffer twice and with acetonitrile once. Feature 210 
intensities were determined using Agilent Feature Extraction Software. Microarray data 211 
were processed and normalized using R and the BioConductor package LIMMA (Linear 212 
Models for Microarray Data) [20]. Raw data quality was assessed using pseudoMA and 213 
box plots. A background correction was applied and normalization of the green channel 214 
between arrays was done using ‘cyclicloess’ between pairs of arrays. Control and low-215 
expressed probes were removed and only those probes brighter than the negative controls 216 
(≥ 10%) on at least one array were kept. Batch-corrected data were obtained using 217 
removeBatchEffect based on ‘Batch’ [20]. Probes with no associated gene ID were 218 
removed. Finally, data were averaged based on an association to a particular gene.  219 
 220 
  221 
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HIGH-RESOLUTION ULTRASONOGRAPHY CAROTID EVALUATION 222 
Carotid arteries were assessed using a Siemens Acuson S2000 (Mochida Siemens 223 
Medical System, Tokyo, Japan) ultrasound system with a 7.5 MHz linear array 224 
transducer. Images were independently evaluated by two radiologists blinded to clinical 225 
and laboratory data. cIMT values were manually measured in 12 carotid segments: 226 
internal (i) and external walls (e) of the right and left common carotid arteries (CCA) in 227 
a proximal segment (proCCA), in a plaque-free segment 10 mm from the bifurcation 228 
(preCCA) and in the internal carotid arteries (ICA). For the left and right arteries, the 229 
mean CCA and ICA values for each subject were calculated from these four 230 
measurements (mRCCA and mLCCA) and two measurement (mRICA and mLICA), 231 
respectively. The average of all measurements was reported as overall cIMT (mCA). Sub-232 
clinical atherosclerosis was defined as a cut-off value of overall cIMT >0.78 mm [21]. A 233 
plaque was defined as a focal thickening ≥1.2 mm in any of 12 carotid segments (near 234 
and far walls of the right and left common carotid arteries, bifurcation and internal carotid 235 
artery). 236 
 237 
STATISTICAL ANALYSES 238 
Univariate statistics. Data distribution and normality of variables were checked visually, 239 
and using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Baseline characteristics are 240 
presented as means ± SEM or as median [interquartile range (IQR)] if the distribution 241 
was not normal. Baseline differences in laboratory and anthropometric variables were 242 
assessed using a t-test and a Mann-Whitney U test for normally- and non-normally 243 
distributed variables, respectively. Since most variables were found to be skewed, partial 244 
Spearman’s rank correlation was used to test the relationship between clinical variables 245 
and APOA1BP, SREBF and NOTCH mRNAs adjusting for age, sex, BMI and country. 246 
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Analyses were performed with SPSS software (version 23, IBM SPSS Statistics) and 247 
MATLAB R2014a. Levels of statistical significance were set at P < 0.05. 248 
Multivariate statistics. Transcriptomic and metabolomic data multivariate statistics were 249 
performed in MATLAB R2014a using in-house scripts. This included principal 250 
component analysis (PCA) and orthogonal partial least squares (O-PLS) regression on 251 
the mean-centered and unit variance-scaled variables. Unsupervised PCA was first 252 
applied to visualize the global variance of the data sets to reveal intrinsic similarities, 253 
possible confounders, and to identify strong and moderate outliers based on Hotelling’s 254 
T2 and distance to the model, respectively. Then, supervised O-PLS regression models 255 
were built to identify transcriptomic or metabolic features associated with the variables 256 
of interest. Here, the omics profiles were used as the descriptor matrix (X) to predict the 257 
response variable (Y). Significant features were selected based on the O-PLS regression 258 
loadings adjusted for multiple testing using the Benjamini-Hochberg procedure for false 259 
discovery rate (FDR). A pFDR < 0.05 was used as the reference feature selection 260 
criterion. Finally, each individual variable identified form multivariate models was 261 
further validated by partial Spearman’s correlation adjusting for age, BMI, sex and 262 
country. The predictive performance of the model (Q2Y) was calculated using a leave-263 
one-out cross-validation approach and model validity was established by permutation 264 
testing (1000 permutations). 265 
 266 




The baseline characteristics of the study participants are shown in Table 1. 269 
ASSOCIATIONS OF APOA1BP-SREBF-NOTCH AXIS WITH 270 
CARDIOVASCULAR AND HAEMATOLOGICAL PARAMETERS  271 
APOA1BP had significant inverse associations with several measures of cIMT, including 272 
RICAe, RproCCAi, LpreCCAi, LpreCCAe, mLCCA, mCCA, and mCA thickness 273 
(Figure 1a). Conversely, the expression levels of SREBF1 correlated positively with 274 
cIMT measures in all segments of the left carotid artery (proximal, pre-bifurcation, 275 
internal) and plaque presence. SREBF2 expression only correlated positively with 276 
RpreCCAe. Among the Notch receptors isoforms, NOTCH2NL had the strongest 277 
correlations with cIMT measures. In particular, it had strong correlations with all 278 
measures of the right internal carotid artery, whereas the expression levels of NOTCH1 279 
and NOTCH4 were positively correlated with measures in the left carotid artery. Among 280 
these genes, only SREBF1 had a positive association with the steatosis degree (Figure 281 
1b). We also correlated the mean of the 12 CCA segments (mCCA) with the expression 282 
of all genes involved in cholesterol metabolism. Notably, SREBF1 was the only gene that 283 
correlated positively with mCCA, whereas APOA1BP was amongst those having a 284 
stronger negative correlation (Figure 1c). Similar results were obtained when mCA was 285 
dichotomized based on a subclinical atherosclerosis cut-off >0.78 mm (Supplementary 286 
Figure 1a). 287 
Given that atherosclerosis is considered a chronic inflammation disease, we examined the 288 
associations of atherosclerosis measures with the plasma levels of N-acetylglycoproteins 289 
(NAG) measured by NMR. NAG is a novel composite biomarker of systemic 290 
inflammation that integrates both protein levels and glycosylation states of several of the 291 
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most abundant acute phase proteins in serum [22]. As expected, NAG levels correlated 292 
positively several cIMT measures (Supplementary Figure 1b). As, atherosclerosis is 293 
driven by the progressive accumulation of lipids and leukocytes in the arterial wall, we 294 
also analysed the association between the expression of the previous genes and lipid and 295 
haematological parameters (Figure 1 and Supplementary Figure 1c). Specifically, the 296 
expression of APOA1BP correlated negatively with WBC counts (Figure 1d), whereas 297 
SREBF1 and NOTCH2NL had a positive correlation with RBC (Figure 1e) and WBC 298 
(Figure 1f) counts, respectively. The levels of HDL cholesterol (HDL-C) correlated 299 
positively with APOA1BP expression (Figure 1g), but negatively with the expression of 300 
SREBF1 (Figure 1h). The later also had a positive correlation with the circulating 301 
triglyceride (TG) concentration (Figure 1i). Total WBC counts, and in particular 302 
lymphocytes and monocytes, also correlated positively with several atherosclerosis 303 
measures (Supplementary Figure 1d). 304 
APOA1BP and SREBF ASSOCIATIONS WITH CHOLESTEROL AND NOTCH 305 
PATHWAY GENES 306 
O-PLS models were built to identify genes involved in the Notch signalling (n=79 genes; 307 
Supplementary Table 1) and cholesterol synthesis pathways (n=109 genes; 308 
Supplementary Table 2) associated with APOA1BP, SREBF1, and SREBF2 expression. 309 
In the case of APOA1BP, significant O-PLS models with a good predictability were 310 
obtained for both Notch pathway- (Figure 1j) and cholesterol pathway-associated genes 311 
(Figure 1k). Significant genes identified from multivariate O-PLS regression models were 312 
further validated by partial Spearman’s correlation adjusting for age, BMI, sex, and 313 
country (Figure 1l,m). Remarkably, the expression of all Notch receptors (NOTCH1, 314 
NOTCH2, NOTCH2NL, NOTCH3, NOTCH4) and Jagged ligands (JAG1, JAG2), but not 315 
that of delta-like ligands, was negatively associated with the APOA1BP expression 316 
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(Figure 1l). The expression of APOA1BP was also associated with the expression of 317 
cholesterol transporters such as ABCA1 and SCARB1 (Figure 1m). Significant O-PLS 318 
models were also obtained for the associations between SREBF1 expression and genes 319 
from both Notch and cholesterol pathways (Supplementary Figure 2a,b). Notably, after 320 
partial Spearman’s validation (Supplementary Figure 2c,d), the SREBF1 expression was 321 
positively associated with NOTCH1 and ABCA1, which we had found to be negatively 322 
associated with APOAB1P. Contrary to SREBF1 results, we did not obtain a significant 323 
O-PLS between the expression of SREBF2 and Notch pathway genes (Q2Y=-0.21). 324 
Finally, an O-PLS regression model between cholesterol synthesis pathway genes and 325 
NOTCH2NL identified a negative association with APOA1BP, whereas ABCA1 had the 326 
strongest positive association (Supplementary Figure 2e,f). 327 
ASSOCIATIONS OF THE APOA1BP-SREBF-NOTCH AXIS WITH THE SERUM 328 
METABOLIC PROFILES 329 
O-PLS regression models were built to identify serum metabolites associated with the 330 
expression of APOA1BP, SREBF1, and SREBF2. A significant O-PLS model was 331 
obtained for the prediction of APOA1BP expression levels from the serum metabolic 332 
profile (Figure 2a). Significant identified metabolites (Figure 2b) were further validated 333 
by partial Spearman’s correlation (Figure 2c). We identified asparagine, glycerol, 334 
histidine, glycine, choline and citrate as positively associated with the expression of 335 
APOA1BP, whereas glyceryl of lipids and very low level cholesterol in VLDL were 336 
associated negatively. Metabolites associated positively with APOA1BP had negative 337 
associations with atherosclerosis measures, particularly LmCCA (Figure 2g-i). We also 338 
found a borderline significant negative (r = -0.22, P = 0.051) association between the 339 
expression of APOA1BP and the inflammatory marker NAG. Metabolome-wide 340 
association studies (MWAS) were also performed for the liver expression of SREBF1 and 341 
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SREBF2 using O-PLS multivariate regressions (Figure 2d,e and Supplementary Figure 342 
3a) confirmed by partial Spearman’s correlation (Figure 2 f and Supplementary Figure 343 
3b). As expected, the expression of both genes was positively associated with several 344 
lipids. They also had positive associations with inflammatory markers (NAG), branched-345 
chain amino acids (BCAA) (valine, isoleucine) and related catabolites (α-346 
ketoisovalerate), lactate and proline. Most of these metabolites had positive correlations 347 
with cIMT measures. In particular, BCAA had positive associations with RICAe (Figure 348 
2j-l), whereas NAG and α-ketoisovalerate had positive associations with mCA (R=0.27, 349 
P=0.028; and R=0.33, P=0.006, respectively). 350 
 351 
ASSOCIATIONS OF HAEMATOPOIESIS AND LIPIDS WITH THE SERUM 352 
METABOLIC PROFILES 353 
O-PLS regression models were also constructed to reveal associations between those 354 
haematological and lipid parameters associated with the APOA1BP-SREBF-NOTCH axis 355 
and the serum metabolome. A significant model with a strong predictive ability (Figure 356 
3a) was obtained between the serum metabolic profile and the HDL-C levels. After 357 
validation of the multivariate-identified metabolites by partial Spearman correlation, 358 
metabolites associated with HDL-C were similar to those linked to APOA1BP and 359 
SREBF1 (Figure 3b). Hence, phosphocholine, choline, glycerol, and glycine, which 360 
correlated positively with the expression of APOA1BP, also had a positive correlation 361 
with HDL-C. Conversely, several lipids, inflammation-related metabolites (NAG), 362 
BCAA (valine, isoleucine) and lactate, which were positively associated with SREBF1, 363 
had a negative association with the circulating levels of HDL-C. Notably, the expression 364 
of NOTCH2NL correlated negatively with the serum choline and phosphocholine levels 365 
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(Figure 3c,d) but positively with the BCAAs leucine and isoleucine (Figure 3e,f). It also 366 
had a trend towards a positive association with NAG (r = 0.20, P = 0.07). A significant 367 
O-PLS regression model was also obtained between the fasting serum TG levels and the 368 
serum metabolome (Figure 3g). Patients with higher TG concentrations had higher levels 369 
of several lipids, BCAAs and catabolites (isoleucine, α-ketoisovalerate), inflammation-370 
related metabolites (NAG), aspartate, proline, and acetone (Figure 3h). As expected, these 371 
results agree with those metabolites positively associated with SREBF1. Interestingly, 372 
several metabolites negatively associated with TG, including glycine, asparagine, 373 
phosphocholine, glycerol, and histidine, were found to be positively associated with the 374 
expression of APOA1BP. Finally, O-PLS regression models (Figure 3i) confirmed by 375 
partial Spearman’s correlation (Figure 3j) revealed that serum metabolites positively 376 
associated with the leukocyte counts were similar to those associated with the expression 377 
of SREBF1.  378 
 379 
Discussion 380 
Atherosclerosis and its progression is caused by lipid accumulation and local 381 
inflammation of blood vessels, and is the major underlying cause of CVD. High plasma 382 
concentrations of HDL have shown anti-atherogenic potential because HDL carries 383 
excess cholesterol away from cells. Importantly, human studies have shown that HDL 384 
cholesterol efflux capacity, a metric of HDL function that characterizes a key step in RCT, 385 
may be athero-protective [1,3]. Recent in vitro and animal studies have shown that AIBP 386 
may protect against atherosclerosis [5–8]. Here, we provided evidence for the first time, 387 
to our knowledge, in humans of an inverse association between the expression of 388 
APOA1BP and atherosclerosis measures. 389 
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In vitro studies have demonstrated a role of AIBP in promoting cholesterol efflux from 390 
human umbilical vein endothelial cells to HDL and THP-1-derived macrophages, thereby 391 
reducing lipid accumulation [5,6]. Mechanistically, AIBP enhances cholesterol efflux and 392 
RCT by preventing ABCA1 protein degradation through facilitating its binding to 393 
APOA1 on the cell membrane, thereby increasing ABCA1 levels [5]. Growing evidence 394 
suggests that ABCA1 protects from atherosclerosis by exporting excess cholesterol from 395 
cells to poorly lipidated APOA1, which is essential for the biogenesis of nascent HDL in 396 
hepatocytes [23]. Recent animals studies have also highlighted the protection of AIBP 397 
against atherosclerosis [7,8]. Hence, Apoe-/- mice with established atherosclerosis and 398 
treated with recombinant adeno-associated virus (rAAV) to overexpress AIBP showed 399 
reduction of atherosclerotic plaque size and inflammation but increased circulating HDL 400 
levels and RCT to the liver [8]. In the latter model, AIBP was overexpressed in the aorta 401 
and peritoneal macrophages, but mainly in the liver. The striking increase in ABCA1 402 
protein levels in the aortas and peritoneal macrophages of AIBP-treated mice suggests 403 
again that the effects of AIBP are mediated through ABCA1. In another animal study, 404 
Apoa1bp-/-Ldlr-/- mice fed a high-fat, high-cholesterol diet had exacerbated weight gain, 405 
liver steatosis, hyperlipidaemia and atherosclerosis compared to Ldlr-/- mice [7]. In 406 
addition, AAV-mediated overexpression of AIBP in Ldlr-/- mice protected against weight 407 
gain, plasma lipid increase and atherosclerosis compared to controls.  408 
In agreement with these results, we found negative associations between APOA1BP 409 
expression levels and measures of cIMT. Conversely, we found a negative association 410 
between the expression levels of APOA1BP and ABCA1. It is possible that in patients 411 
with reduced hepatic APOA1BP expression, there is a compensatory response in the 412 
expression of ABCA1 to increase cholesterol efflux in the liver. In addition, although 413 
treatment with AIBP increased ABCA1 protein levels in macrophages and Apoe-/- mice, 414 
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it did not alter the ABCA1 mRNA expression [5,8]. In fact, ABCA1 protein levels and 415 
mRNA expression are usually discordant as ABCA1 protein levels are regulated by a 416 
diverse posttranscriptional mechanism [24]. In contrast to ABCA1, which is important 417 
for the generation of nascent HDL, scavenger receptor class B member 1 (SR-BI) is a 418 
receptor for mature HDL and mediates selective uptake of HDL cholesteryl esters into 419 
the liver as the final step in RCT [25]. Consistently, we found a significant association 420 
between APOA1BP and SCARB1, which encodes the SR-BI protein, which was opposite 421 
to the APOA1BP-ABCA1 correlation.  422 
In addition to the ABCA1 transporter pathway, the VLDL-APOB secretion pathway has 423 
been proposed as the major pathway for the secretion of cholesterol from hepatocytes 424 
together with TG into plasma [26]. Interestingly, the VLDL secretion pathway is 425 
modulated by SREBP1c [27], encoded by SREBF1, which we found strongly positively 426 
associated with atherosclerosis. Specifically, SREBF1 correlated with cIMT measures in 427 
all segments of the left carotid artery, which is in agreement the higher vulnerability of 428 
the left carotid artery to atherosclerosis [28,29]. Hepatic expression of SREBP1c is also 429 
increased in hepatic steatosis [30], which is consistent with our results. A recent study in 430 
zebrafish has shown that Aibp2-mediated HPSC expansion through the up-regulation of 431 
Srebf2 (but not Srebf1), which predominantly regulates cholesterol synthesis [14]. 432 
Although we mainly found SREBF1 associated with cIMT rather than SREBF2, it is worth 433 
noting that SREBF1 is transcribed into two variants: SREBP-1c, which solely regulates 434 
lipid synthesis, and SREBP-1a, which controls both cholesterol and lipid synthesis. AIBP  435 
also seem to modulate Notch signalling in mice and zebrafish [13,14]. In agreement with 436 
these results, we found strong associations between the expression of APOA1BP and the 437 
expression of all Notch signalling receptors and jagged ligands, but not with delta-like 438 
ligands. Interestingly, jagged and delta-like ligands have shown opposite effects on 439 
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angiogenesis and regulation of T cells [31,32]. Consistent with a higher susceptibility of 440 
the left carotid artery, we also found that NOTCH1 and NOTCH4 were positively 441 
associated with left cIMT measures. Despite these associations, it is particularly 442 
noticeable that the expression of human-specific gene NOTCH2NL had the strongest 443 
associations with atherosclerotic measures. Interestingly, among all genes involved in 444 
cholesterol metabolism, NOTCH2NL had the strongest positive association with ABCA1, 445 
suggesting again a potential upregulation of ABCA1 expression to increase cholesterol 446 
efflux in patients with cIMT. Little is known about NOTCH2NL, but it has recently stood 447 
out for its ability to enhance Notch signalling and expand human cortical progenitor cells 448 
[33,34]. Consistent with this link between cholesterol metabolism and haematopoiesis, 449 
we found significant associations among the expression of APOA1BP, SREBF1 and 450 
NOTCH2NL, and haematology and lipid parameters. 451 
We found that the expression of transcripts APOA1BP, SREBF1, SREBF2 and 452 
NOTCH2NL was associated with several plasma metabolites. APOA1BP had positive 453 
correlations with three amino acids (asparagine, histidine, glycine), glycerol, choline and 454 
citrate. These amino acids were also associated positively with circulating HDL-C levels, 455 
but negatively with TG and WBC counts. Glycine, histidine and asparagine were also 456 
negatively associated with cIMT measures. Of note, among 35 plasma metabolites 457 
quantified in 1049 individuals without coronary artery disease (CAD) and diabetes, 458 
histidine was most strongly associated with lower risk for incident CAD, followed by 459 
asparagine [35]. Low circulating levels of glycine have also been causally associated with 460 
higher incidence of coronary heart disease [36].  461 
APOA1BP expression also had a positive association with choline. Remarkably, both 462 
choline and phosphocholine levels had very strong positive associations with HDL-C but 463 
correlated negatively with the expression of NOTCH2NL. There is evidence suggesting a 464 
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connection between choline and HDL metabolism. Hence, phosphatidylcholine is the 465 
major phospholipid component of all plasma lipoproteins and the biosynthesis of 466 
phosphatidylcholine in the liver is critical for the synthesis and secretion of HDL and 467 
VLDL [37]. Interestingly, APOA1BP correlated negatively with the expression of liver 468 
enzymes involved in the synthesis of phosphatidylcholine from choline and 469 
phosphocholine, suggesting an up-regulation of the synthesis of phosphatidylcholine in 470 
patients with lower APOA1BP to increase assembly and clearance of lipoproteins. Due to 471 
the role of lecithin–cholesterol acyltransferase (LCAT) in the formation of HDL and 472 
RCT, we also assessed the relation between the expression levels of APOA1BP and LCAT 473 
and found a positive association (R=0.27, P=0.01). Interestingly, although studies in the 474 
general population gave inconsistent results, patients with LCAT deficiency have shown 475 
a significant increase in the incidence of CVD [38]. Despite the associations with 476 
APOA1BP and HDL, neither choline nor phosphocholine had associations with measures 477 
of atherosclerosis. Previous studies have shown inconsistent associations between 478 
circulating choline and phosphocholine levels and cardiovascular events. Both 479 
metabolites were positively associated with the risk of CVD and stroke after 4.8 years of 480 
follow-up in participants at high cardiovascular risk within the PREDIMED study, but no 481 
associations were found between 1-year changes in these metabolites and the incidence 482 
of CVD [39]. Similarly, higher plasma choline levels were associated with increased risk 483 
of major cardiac events after 3 years of follow-up in patients undergoing elective 484 
diagnostic coronary angiography, but they did not predict risk when trimethylamine N-485 
oxide, a choline metabolite, was added to the model [40]. In cross-section studies higher 486 
plasma choline concentrations have been associated with an unfavourable 487 
cardiometabolic risk factor profile, including lower HDL levels [41,42]. However, it is 488 
worth noting that plasma choline levels do not reflect choline status because disturbances 489 
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in circulating choline arise early in disease development [43,44] and circulating levels 490 
may depend on lipid overload. In this sense, plasma choline metabolites differed between 491 
normal and overweight men [45]. In addition, both low and high plasma concentrations 492 
may be associated with adverse effects [46]. 493 
As expected, the expression levels of SREBF1 and SREBF2 had positive associations with 494 
several lipids. These genes also correlated positively with circulating levels of BCAA and 495 
catabolites, NAG and lactate. Except for lactate, we found that these metabolites were all 496 
positively associated with measure of cIMT. Several cross-section and prospective cohort 497 
studies revealed positive associations of BCAA with major metabolic disorders [47] and 498 
recently they have also been positively associated with risk factors of CAD, in particular 499 
cIMT [48]. Interestingly, we also found a positive correlation between the expression 500 
levels of NOTCH2NL and BCAA. In line with atherosclerosis being a chronic 501 
inflammatory disorder, we found a consistent association between NAG, a novel marker 502 
of chronic inflammation [22], and cIMT measures. Consistently, we found that NAG 503 
levels were the strongest predictors of WBC counts, which also had positive associations 504 
with BCAA. Supporting the role of the APOA1BP-SREBF-NOTCH axis and 505 
inflammation in atherosclerosis, we also found that NAG levels were negatively 506 
associated with the expression of APOA1BP, but positively with that of SREBF1, 507 
SREBF2, and NOTCH2NL. Finally, most of the metabolites associated with SREBF1 and 508 
SREBF2 had similar associations with TG, but opposite to those of HDL. 509 
The main limitation of our study is its cross-sectional nature. Therefore, we cannot infer 510 
cause-effect relationships. Second, the results cannot be extrapolated to the general 511 
population, as subjects in the current study were morbidly obese. In addition, we did not 512 
measure AIBP protein levels. The strengths of the present work include the use of two 513 
independent well-characterized cohorts, which allowed the control for potential 514 
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confounders, with comprehensive metabolomic, transcriptomic, liver biopsy and cIMT 515 
data. 516 
In conclusion, our findings demonstrate, for the first time, an atheroprotective association 517 
between the expression levels of APOA1BP and atherosclerosis in humans. We have also 518 
shown a connection between APO1ABP, Notch signalling and inflammation with 519 
atherosclerosis.  520 
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Figure Legends 691 
Figure 1. Associations of expression levels of APOA1BP, SREBFs, and NOTCHs gens 692 
with cIMT, steatosis, haematology and lipid measures and cholesterol and notch 693 
pathway genes. a) Heatmap displaying the partial Spearman’s correlation coefficients 694 
(adjusted for age, BMI, sex, and cohort) between genes and cIMT measures. *p<0.05, 695 
**p<0.01, ***p<0.001. b) Association of expression levels of SREBF1 with the steatosis 696 
degree (ANCOVA and Tukey-kramer tests). c) Cholesterol metabolism pathway genes 697 
significantly associated with mean CCA based on partial Spearman’s correlation adjusted 698 
for age, BMI, sex, and cohort. d-i) Scatter plots between expression levels of selected 699 
genes and haematological and lipid parameters. Partial Spearman’s correlation and 700 
significance values adjusted for age, BMI, sex, and cohort are shown. j-k)  Permutation 701 
test for the goodness-of-fit (R2Y) and goodness of prediction (Q2Y) obtained from the O-702 
PLS models between the expression levels of APOA1BP and the expression levels of 703 
genes involved in the Notch signalling and cholesterol pathways, respectively. l-m)  704 
Significant Notch and cholesterol pathway genes associated with APOA1BP after further 705 
validation of the O-PLS identified genes by partial Spearman’s correlation adjusting for 706 
age, sex, BMI, and country. 707 
Figure 2. Associations of metabolomics data with the expression levels of APOA1BP, 708 
SREBF1,and cIMT measures. a) Permutation test for the goodness-of-fit (R2Y) and 709 
goodness of prediction (Q2Y) obtained from the O-PLS models between the expression 710 
levels of APOA1BP and the serum metabolome. b) Significant serum metabolites 711 
obtained from the O-PLS model. Statistically significant metabolites are coloured in red 712 
if positively associated with APOA1BP and blue if negatively associated. c) Metabolites 713 
associated with APOA1BP after further validation of the O-PLS identified metabolites by 714 
partial Spearman’s correlation adjusting for age, sex, BMI, and country. d) Permutation 715 
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test for the goodness-of-fit (R2Y) and goodness of prediction (Q2Y) obtained from the O-716 
PLS models between the expression levels of SREBF1 and the serum metabolome. e) 717 
Significant serum metabolites obtained from the O-PLS model. Statistically significant 718 
metabolites are coloured in red if positively associated with SREBF1 and blue if 719 
negatively associated. f) Metabolites associated with SREBF1 after further validation of 720 
the O-PLS identified metabolites by partial Spearman’s correlation adjusting for age, sex, 721 
BMI, and country. g-l) Scatter plots between selected metabolites and cIMT measures. 722 
Partial Spearman’s correlation and significance values adjusted for age, BMI, sex, and 723 
cohort are shown. 724 
Figure 3. Associations of metabolomics data with the lipid parameters, WBC, and 725 
NOTCH2NL expression levels. a) Permutation test for the goodness-of-fit (R2Y) and 726 
goodness of prediction (Q2Y) obtained from the O-PLS models between the expression 727 
levels of HDL-C and the serum metabolome. b) Metabolites associated with HDL-C after 728 
further validation of the O-PLS identified metabolites by partial Spearman’s correlation 729 
adjusting for age, sex, BMI, and country. c-f) Scatter plots between selected metabolites 730 
and NOTCH2NL expression levels. Partial Spearman’s correlation and significance 731 
values adjusted for age, BMI, sex, and cohort are shown. g) Permutation test for the 732 
goodness-of-fit (R2Y) and goodness of prediction (Q2Y) obtained from the O-PLS models 733 
between the expression levels of TG and the serum metabolome. h) Metabolites 734 
associated with TG after further validation of the O-PLS identified metabolites by partial 735 
Spearman’s correlation adjusting for age, sex, BMI, and country. i) Permutation test for 736 
the goodness-of-fit (R2Y) and goodness of prediction (Q2Y) obtained from the O-PLS 737 
models between the expression levels of WBC and the serum metabolome. j) Metabolites 738 
associated with WBC after further validation of the O-PLS identified metabolites by 739 
partial Spearman’s correlation adjusting for age, sex, BMI, and country. 740 
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Supplementary Figure 1. a) Cholesterol metabolism pathway genes significantly 741 
associated with mean CA based on partial Spearman’s correlation adjusted for age, BMI, 742 
sex, and cohort. b) Heatmap displaying the partial Spearman’s correlations (adjusted for 743 
age, BMI, sex, and cohort) between cIMT measures and inflammation measured by NMR 744 
plasma levels of N-acetylglycoproteins (NAG). c) Heatmap displaying the partial 745 
Spearman’s correlation coefficients (adjusted for age, BMI, sex, and cohort) between 746 
genes and haematological parameters. d) Heatmap displaying the partial Spearman’s 747 
correlation coefficients (adjusted for age, BMI, sex, and cohort) between haematological 748 
parameters and cIMT measures. 749 
Supplementary Figure 2. a,b) Permutation test for the goodness-of-fit (R2Y) and 750 
goodness of prediction (Q2Y) obtained from the O-PLS models between the expression 751 
levels of SREBF1 and the expression levels of genes involved in Notch signalling and 752 
cholesterol synthesis pathways, respectively. c,d) Significant Notch signalling and  753 
cholesterol pathway genes associated with SREBF1 after further validation of the O-PLS 754 
identified genes by partial Spearman’s correlation adjusting for age, sex, BMI, and 755 
country, respectively. e) Permutation test for the goodness-of-fit (R2Y) and goodness of 756 
prediction (Q2Y) obtained from the O-PLS models between the expression levels of 757 
NOTCH2NL and the expression levels of genes involved in cholesterol synthesis 758 
pathway. f)  Significant cholesterol pathway genes associated with NOTCH2NL after 759 
further validation of the O-PLS identified genes by partial Spearman’s correlation 760 
adjusting for age, sex, BMI, and country. 761 
Supplementary Figure 3. a) Permutation test for the goodness-of-fit (R2Y) and goodness 762 
of prediction (Q2Y) obtained from the O-PLS models between the expression levels of 763 
SREBF2 and the serum metabolome. b) Significant serum metabolites obtained from the 764 
O-PLS model. Statistically significant metabolites are coloured in red if positively 765 
35 
 
associated with SREBF2 and blue if negatively associated. c) Metabolites associated with 766 
SREBF2 after further validation of the O-PLS identified metabolites by partial 767 




Table 1. Baseline characteristics of participants. 770 
Variables All (n=78) 
Age (years) 42.4 ± 1.16 
BMI (kg/m2) 46.2 (42.4-51.1) 
Waist circumference (cm) 127.0 (119.5-138.0) 
Sex (women, %) 79.2 
SBP (mmHg) 134.0 (122.5-144.0) 
DBP (mmHg) 81.0 (75.0-90.0) 
Biochemistry  
Glucose (mg/dL) 95.0 (88.5-101.5) 
HOMA-IR 4.50 (2.95-6.90) 
Triglycerides (mg/dL) 112.0 (82.0-143.5) 
Total cholesterol (mg/dL) 197.5 ± 4.6 
LDL cholesterol (mg/dL) 131.0 ± 4.0 
HDL cholesterol (mg/dL) 45.0 (40.0-51.2) 
Haematology  
Eosinophils 150.0 (100.0-200.0) 
Neutrophils 4810 (3665-5795) 
Lymphocytes 2360 ± 86.9 
Monocytes 500 (420-600) 
Total WBC 7350 (6385-9030) 
RBC 4.66 (4.46-4.91) 
Liver  
HsCRP 0.88 (0.47-1.39) 
AST 19.0 (15.0-28.0) 
ALT 30.0 (22.0-43.5) 
Steatosis grade (%):  
Grade 0 15.6 
Grade 1 33.8 
Grade 2 24.7 
Grade 3 26.0 
Atherosclerosis  
RproCCAi 0.70 (0.60-0.80) 
RproCCAe 0.70 (0.60-0.80) 
RpreCCAi 0.79 ± 0.03 
RpreCCAe 0.72 (0.60-0.80) 
RICAi 0.70 (0.60-0.90) 
RICAe 0.70 (0.54-0.85) 
mRCCA 0.73 ± 0.02 
mRICA 0.71 ± 0.02 
LproCCAi 0.70 (0.60-0.85) 
LproCCAe 0.69 (0.60-0.80) 
LpreCCAi 0.80 (0.70-1.0) 
LpreCCAe 0.84 ± 0.03 
LICAi 0.77 (0.57-0.90) 
LICAe 0.70 (0.60-0.87) 
mLCCA 0.76 ± 0.02 
mLICA 0.73 ± 0.03 
mCCA 0.74 ± 0.02 
mCA 0.73 ± 0.02 
Values are expressed as means ± SEM for normally distributed variables and median [IQR] for non-normally 771 
distributed variables. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HsCRP, high sensitivity 772 
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C-reactive protein; e, external; i, internal; ICA, internal carotid artery; L, left; m, mean; preCCA, pre bifurcation 773 
common carotid artery; proCCA, proximal segment common carotid artery; R, right; RBC, red blood cells; WBC, 774 
white blood cells. 775 
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Background & Aims: Atherosclerosis is characterized by an inflammatory disease 56 
linked to excessive lipid accumulation in the artery wall. The Notch signalling pathway 57 
has been shown to play a key regulatory role in the regulation of inflammation. Recently, 58 
in vitro and pre-clinical studies have shown that apolipoprotein A-I binding protein 59 
(AIBP) regulates cholesterol metabolism (SREBP) and NOTCH signalling 60 
(haematopoiesis) and may be protective against atherosclerosis, but the evidence in 61 
humans is scarce. 62 
Methods: We evaluated the APOA1BP-SREBF-NOTCH axis in association with 63 
atherosclerosis in two well-characterized cohorts of morbidly obese patients (n = 78) 64 
within the FLORINASH study, including liver transcriptomics, 1H-NMR plasma 65 
metabolomics, high-resolution ultrasonography evaluating carotid intima-media 66 
thickness (cIMT), and haematological parameters. 67 
Results: The liver expression levels of APOA1BP were associated with lower cIMT and 68 
leukocyte counts, a better plasma lipid profile and higher circulating levels of metabolites 69 
associated with lower risk of atherosclerosis (glycine, histidine and asparagine). 70 
Conversely, liver SREBF and NOTCH mRNAs were positively associated with 71 
atherosclerosis, liver steatosis, an unfavourable lipid profile, higher leukocytes and 72 
increased levels of metabolites linked to inflammation and CVD such as branched-chain 73 
amino acids and glycoproteins. APOA1BP and NOTCH signalling also had a strong 74 
association, as revealed by the negative correlations among APOA1BP expression levels 75 
and those of all NOTCH receptors and jagged ligands. 76 
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Conclusions: We here provide the first evidence in human liver of the putative 77 
APOA1BP-SREBF-NOTCH axis signalling pathway and its association with 78 
atherosclerosis and inflammation.  79 
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Atherosclerosis is the major cause of cardiovascular disease (CVD), the leading cause of 80 
death worldwide. Several studies have shown the anti-atherogenic potential of the high-81 
density lipoprotein (HDL)-mediated reverse cholesterol transport (RCT) [1]. In this 82 
process, excess cholesterol is transported from macrophages and peripheral tissues back 83 
to the liver for excretion. A critical part of RCT is cholesterol efflux, in which intracellular 84 
cholesterol is released and collected by apolipoprotein A1 (APOA1), the major 85 
component of HDL [2]. In fact, the cholesterol efflux potential of HDL is a better 86 
predictor of CVD than circulating HDL levels [3]. The ATP-binding cassette transporter 87 
A1 (ABCA1), a cell-membrane protein, is the major transporter that mediates this 88 
assembly of cholesterol with APOA1, which is the rate-limiting step in the formation of 89 
nascent HDLs.  90 
The APOA1 binding protein (AIBP), encoded by APOA1BP in humans, is a secreted 91 
protein physically associated with APOA1 [4] that enhances cholesterol efflux in vitro 92 
from macrophages [5] and endothelial cells [6] in the presence of APOA1 or HDL, partly 93 
by facilitating apoA1 binding to ABCA1 and preventing ABCA1 degradation [5]. 94 
Recently, AIBP has shown to protect against atherosclerosis in vivo in Apoe-/- and Ldlr-/- 95 
mice by promoting cholesterol efflux and ameliorating inflammation [7,8]. Human 96 
APOA1BP mRNA is ubiquitously expressed and abundant in most human secretory 97 
organs, with the highest expression in kidney, heart, liver, thyroid gland, adrenal gland, 98 
and testis [4]. It is of note that kidney and liver are the major sites of APOA1 catabolism. 99 
Atherosclerosis is characterized by progressive accumulation of lipids and leukocytes in 100 
the intima layer of the arterial wall. It is considered a chronic inflammation disease with 101 
monocytes/macrophages, the main immune cells of the innate immune response, playing 102 
a major role in all stages of atherosclerosis [9]. Notably, the Notch pathway is well-103 
recognized as a major regulator of cell fate in stem cells and the differentiation of the 104 
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various cell types of the immune system [10]. Recently, the Notch signalling pathway 105 
was shown to play an important role in the onset and progression of atherosclerosis by 106 
promoting inflammation through induction of a pro-inflammatory M1 phenotype in 107 
macrophages, a switch towards a Th-1 like inflammatory phenotype in differentiated 108 
regulatory T cells, and promoting CD8 cytotoxic T cells [11].  109 
Recent evidence suggests a control of hematopoietic progenitor and stem cells (HPSC) 110 
by cholesterol pathways [12], thereby linking haematopoiesis with atherosclerosis. 111 
Interestingly, a connection between AIBP-mediated cholesterol metabolism and Notch 112 
signalling has been described recently. AIBP was shown to regulate Notch signalling 113 
through relocalization of -secretase from lipid to non-lipid rafts in mice [13] and 114 
zebrafish Aibp2-mediated cholesterol efflux was shown to active endothelial Srebp2, 115 
which in turn trans-activates Notch and promotes HSPC emergence. These observations 116 
suggest a role for the AIBP-SREBP-NOTCH axis in atherosclerosis [14]. Although the 117 
bone marrow is the primary site of haematopoiesis in adults, the liver is the main site 118 
during prenatal development and hepatic haematopoiesis is believed to persist into 119 
adulthood [15,16]. 120 
No study has, to date, addressed the potential association between AIBP and Notch 121 
signalling in humans. Here, we studied this connection in two well-characterized cohorts 122 
of morbidly obese patients recruited to the FLORINASH study (17) combining hepatic 123 
transcriptome, plasma metabolome, and carotid intima-media thickness (cIMT) 124 
measures. 125 
  126 
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Subjects and Methods 127 
STUDY POPULATION AND SAMPLE COLLECTION 128 
The study population (n = 78) included two cohorts of morbidly obese patients aged 22 129 
to 61 years old recruited at the Endocrinology Service of the Hospital Universitari de 130 
Girona Dr Josep Trueta (Girona, Spain, n = 32) and at the Center for Atherosclerosis of 131 
Policlinico Tor Vergata University of Rome (Rome, Italy, n = 46), as part of the 132 
FLORINASH study [17]. All subjects gave written informed consent, which was 133 
validated and approved by the ethical committees of the Hospital Universitari Dr Josep 134 
Trueta (Comitè d’Ètica d’Investigació Clínica, approval number 2009 046) and 135 
Policlinico Tor Vergata University of Rome (Comitato Etico Indipendente, approval 136 
number 28-05-2009). Inclusion criteria included Caucasian origin, stable body weight 3 137 
months before the study, free of any infection one month preceding the study and absence 138 
of any systemic disease. Exclusion criteria included presence of liver disease and thyroid 139 
dysfunction, alcohol consumption (> 20 g/day), hepatitis B, drug-induced liver injury, 140 
and dyslipidaemia medication. Plasma samples were obtained during the week before 141 
elective gastric bypass surgery, during which a liver biopsy was sampled. All samples 142 
were stored at −80 °C. Liver samples were collected in RNAlater, fragmented and 143 
immediately flash frozen in liquid nitrogen before storage at −80 °C.  144 
 145 
ANTHROPOMETRIC AND LABORATORY MEASUREMENTS 146 
Blood pressure was measured using a blood pressure monitor (Hem-703C, Omron, 147 
Barcelona, Spain), with the subject seated and after 5 min of rest. Three readings were 148 
obtained and the mean value was used in the analyses. Waist circumference was measured 149 
with a soft tape midway between the lowest rib and the iliac crest. Obesity was considered 150 
as a body mass index (BMI) ≥ 30 kg/m2.  151 
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After 8 h fasting, blood was drawn for the measurement of plasma lipids, glucose and 152 
insulin. Glucose and lipids were determined by standard laboratory methods. Intra-assay 153 
and inter-assay coefficients of variation (CV) were less than 4 %. Serum insulin was 154 
measured in duplicate using a monoclonal immunoradiometric assay (Medgenix 155 
Diagnostics, Fleunes, Belgium). The intra-assay CV was 5.2 % at a concentration of 10 156 
mU/L and 3.4 % at 130 mU/L. The interassay CVs were 6.9 % and 4.5 % at 14 and 89 157 
mU/L, respectively. Glycated haemoglobin (HbA1c) was measured by high-pressure 158 
liquid chromatography using a fully automated glycated haemoglobin analyser system 159 
(Hitachi L-9100; Hitachi, Tokyo, Japan). Insulin resistance was determined by the 160 
homeostasis model assessment of insulin resistance (HOMA-IR). High sensitive C-161 
reactive protein (HsCRP) was determined by ultrasensitive assay (Beckman, Fullerton, 162 
CA), with intra-and inter-assay CVs of 4 %. Serum alanine aminotransferase (ALT) and 163 
aspartate aminotransferase (AST) levels were determined using enzymatic methods. 164 
 165 
LIVER HISTOLOGY 166 
Liver biopsies were analysed by a single pathologist expert in hepatic pathology. For each 167 
liver sample, haematoxylin and eosin, reticulin, and Masson’s trichrome staining were 168 
performed. Hepatic steatosis grade was determined according to the scoring system for 169 
NAFLD and defined as absent (grade 0: <5% steatosis), mild (grade 1: 5-33% steatosis), 170 
moderate (grade 2: >33-66% steatosis) or severe (grade 3: >66% steatosis) [18]. Images 171 
were independently evaluated by two radiologists blinded to clinical and laboratory data. 172 
 173 
  174 
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1H NUCLEAR MAGNETIC RESONANCE (1H-NMR) METABOLIC 175 
PROFILING  176 
Metabolomics analyses have been previously described [17]. Briefly, plasma samples 177 
were thawed at room temperature and 350 µL aliquots were carefully placed in 5-mm 178 
NMR tubes. Then, 150 µL of saline solution (0.9 % NaCl) were added and the mixture 179 
was gently vortexed. Spectroscopic analyses were performed on a Bruker DRX600 180 
spectrometer equipped with either a 5-mm TXI probe operating at 600.13 MHz or a 5-181 
mm BBI probe operating at 600.44 MHz. Spectra were acquired using a water suppressed 182 
Carr-Purcell-Meiboom-Gill using the Bruker program cpmgpr (RD 90º-(-180º-) n-183 
acquire). A RD of 2 s was employed for net magnetization relaxation, during which noise 184 
irradiation was applied in order to suppress the large water proton signal. A number of 185 
loops n = 100 and a spin-echo delay  = 400 µs was used to allow spectral editing through 186 
T2 relaxation and therefore attenuation of broad signals. For each sample, 128 scans were 187 
recorded in 32K data points with a spectral with of 20 ppm. All NMR spectra were 188 
processed using Topspin (Bruker Biospin, UK). Free induction decays were multiplied 189 
by an exponential function corresponding to a line broadening of 0.3 Hz and Fourier 190 
transformed. Spectra were automatically phased, baseline-corrected and referenced to the 191 
anomeric doublet of glucose (5.23 ppm). The spectra were all then imported to MATLAB 192 
and the region around the water resonance (=4.5-5.0) was removed.  193 
 194 
TRANSCRIPTOMICS 195 
Transcriptomic analyses have been previously described [17]. Briefly, RNA from liver 196 
biopsy samples was extracted using standard extraction protocols (TRIzol) by Miltenyi 197 
Biotec as previously reported. RNA quality (gel images, RNA integrity number and 198 
electropherograms) was assessed using an Agilent 2100 Bioanalyzer platform (Agilent 199 
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Technologies). An RNA integrity number >6 was considered sufficient for gene 200 
expression experiments [19]. One-hundred ng of total RNA were used for linear T7-based 201 
amplification of RNA for each sample. cDNA was prepared by amplification of the RNA 202 
and labelled with Cy3 using the Agilent Low Input Quick Amp Labeling Kit according 203 
to the manufacturer’s instructions. The amounts of cDNA and dye that were incorporated 204 
were measured by an ND-1000 spectrophotometer (NanoDrop Technologies). 205 
Hybridization of the Agilent Whole Human Genome Oligo Microarrays 4 × 44K was 206 
done following the Agilent 60-mer oligo microarray processing protocol using the 207 
Agilent Gene Expression Hybridization Kit. The fluorescence signals of the hybridized 208 
Agilent microarrays were detected using Agilent’s Microarray Scanner after washing 209 
with Agilent Gene Expression Wash Buffer twice and with acetonitrile once. Feature 210 
intensities were determined using Agilent Feature Extraction Software. Microarray data 211 
were processed and normalized using R and the BioConductor package LIMMA (Linear 212 
Models for Microarray Data) [20]. Raw data quality was assessed using pseudoMA and 213 
box plots. A background correction was applied and normalization of the green channel 214 
between arrays was done using ‘cyclicloess’ between pairs of arrays. Control and low-215 
expressed probes were removed and only those probes brighter than the negative controls 216 
(≥ 10%) on at least one array were kept. Batch-corrected data were obtained using 217 
removeBatchEffect based on ‘Batch’ [20]. Probes with no associated gene ID were 218 
removed. Finally, data were averaged based on an association to a particular gene.  219 
 220 
  221 
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HIGH-RESOLUTION ULTRASONOGRAPHY CAROTID EVALUATION 222 
Carotid arteries were assessed using a Siemens Acuson S2000 (Mochida Siemens 223 
Medical System, Tokyo, Japan) ultrasound system with a 7.5 MHz linear array 224 
transducer. Images were independently evaluated by two radiologists blinded to clinical 225 
and laboratory data. cIMT values were manually measured in 12 carotid segments: 226 
internal (i) and external walls (e) of the right and left common carotid arteries (CCA) in 227 
a proximal segment (proCCA), in a plaque-free segment 10 mm from the bifurcation 228 
(preCCA) and in the internal carotid arteries (ICA). For the left and right arteries, the 229 
mean CCA and ICA values for each subject were calculated from these four 230 
measurements (mRCCA and mLCCA) and two measurement (mRICA and mLICA), 231 
respectively. The average of all measurements was reported as overall cIMT (mCA). Sub-232 
clinical atherosclerosis was defined as a cut-off value of overall cIMT >0.78 mm [21]. A 233 
plaque was defined as a focal thickening ≥1.2 mm in any of 12 carotid segments (near 234 
and far walls of the right and left common carotid arteries, bifurcation and internal carotid 235 
artery). 236 
 237 
STATISTICAL ANALYSES 238 
Univariate statistics. Data distribution and normality of variables were checked visually, 239 
and using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Baseline characteristics are 240 
presented as means ± SEM or as median [interquartile range (IQR)] if the distribution 241 
was not normal. Baseline differences in laboratory and anthropometric variables were 242 
assessed using a t-test and a Mann-Whitney U test for normally- and non-normally 243 
distributed variables, respectively. Since most variables were found to be skewed, partial 244 
Spearman’s rank correlation was used to test the relationship between clinical variables 245 
and APOA1BP, SREBF and NOTCH mRNAs adjusting for age, sex, BMI and country. 246 
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Analyses were performed with SPSS software (version 23, IBM SPSS Statistics) and 247 
MATLAB R2014a. Levels of statistical significance were set at P < 0.05. 248 
Multivariate statistics. Transcriptomic and metabolomic data multivariate statistics were 249 
performed in MATLAB R2014a using in-house scripts. This included principal 250 
component analysis (PCA) and orthogonal partial least squares (O-PLS) regression on 251 
the mean-centered and unit variance-scaled variables. Unsupervised PCA was first 252 
applied to visualize the global variance of the data sets to reveal intrinsic similarities, 253 
possible confounders, and to identify strong and moderate outliers based on Hotelling’s 254 
T2 and distance to the model, respectively. Then, supervised O-PLS regression models 255 
were built to identify transcriptomic or metabolic features associated with the variables 256 
of interest. Here, the omics profiles were used as the descriptor matrix (X) to predict the 257 
response variable (Y). Significant features were selected based on the O-PLS regression 258 
loadings adjusted for multiple testing using the Benjamini-Hochberg procedure for false 259 
discovery rate (FDR). A pFDR < 0.05 was used as the reference feature selection 260 
criterion. Finally, each individual variable identified form multivariate models was 261 
further validated by partial Spearman’s correlation adjusting for age, BMI, sex and 262 
country. The predictive performance of the model (Q2Y) was calculated using a leave-263 
one-out cross-validation approach and model validity was established by permutation 264 
testing (1000 permutations). 265 
 266 




The baseline characteristics of the study participants are shown in Table 1. 269 
ASSOCIATIONS OF APOA1BP-SREBF-NOTCH AXIS WITH 270 
CARDIOVASCULAR AND HAEMATOLOGICAL PARAMETERS  271 
APOA1BP had significant inverse associations with several measures of cIMT, including 272 
RICAe, RproCAAiRproCCAi, LpreCCAi, LpreCCAe, mLCCA, mCCA, and mCA 273 
thickness (Figure 1a). Conversely, the expression levels of SREBF1 correlated positively 274 
with cIMT measures in all segments of the left carotid artery (proximal, pre-bifurcation, 275 
internal) and plaque presence. SREBF2 expression only correlated positively with 276 
RpreCCAe. Among the Notch receptors isoforms, NOTCH2NL had the strongest 277 
correlations with cIMT measures. In particular, it had strong correlations with all 278 
measures of the right internal carotid artery, whereas the expression levels of NOTCH1 279 
and NOTCH4 were positively correlated with measures in the left carotid artery. Among 280 
these genes, only SREBF1 had a positive association with the steatosis degree (Figure 281 
1b). We also correlated the mean of the 12 CCA segments (mCCA) with the expression 282 
of all genes involved in cholesterol metabolism. Notably, SREBF1 was the only gene that 283 
correlated positively with mCCA, whereas APOA1BP was amongst those having a 284 
stronger negative correlation (Figure 1c). Similar results were obtained when mCA was 285 
dichotomized based on a subclinical atherosclerosis cut-off >0.78 mm (Supplementary 286 
Figure 1a). 287 
Given that atherosclerosis is considered a chronic inflammation disease, we examined the 288 
associations of atherosclerosis measures with the plasma levels of N-acetylglycoproteins 289 
(NAG) measured by NMR. NAG is a novel composite biomarker of systemic 290 
inflammation that integrates both protein levels and glycosylation states of several of the 291 
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most abundant acute phase proteins in serum [22]. As expected, NAG levels correlated 292 
positively several cIMT measures (Supplementary Figure 1b). As, Aatherosclerosis is 293 
characterized driven by the progressive accumulation of lipids and leukocytes in the 294 
arterial wall, . Therefore, we also analysed the association between the expression of the 295 
previous genes and lipid and haematological parameters (Figure 1 and Supplementary 296 
Figure 1c). Specifically, Tthe expression of APOA1BP correlated negatively with WBC 297 
counts (Figure 1d), whereas SREBF1 and NOTCH2NL had a positive correlation with 298 
RBC (Figure 1e) and WBC (Figure 1f) counts, respectively. The levels of HDL 299 
cholesterol (HDL-C) correlated positively with APOA1BP expression (Figure 1g), but 300 
negatively with the expression of SREBF1 (Figure 1h). The later also had a positive 301 
correlation with the circulating triglyceride (TG) concentration (Figure 1i). Total WBC 302 
counts, and in particular lymphocytes and monocytes, also correlated positively with 303 
several atherosclerosis measures (Supplementary Figure 1d). 304 
APOA1BP and SREBF ASSOCIATIONS WITH CHOLESTEROL AND NOTCH 305 
PATHWAY GENES 306 
O-PLS models were built to identify genes involved in the Notch signalling (n=79 genes; 307 
Supplementary Table 1) and cholesterol synthesis pathways (n=109 genes; 308 
Supplementary Table 2) associated with APOA1BP, SREBF1, and SREBF2  expression. 309 
In the case of APOA1BP, Ssignificant O-PLS models with a good predictability were 310 
obtained for both Notch pathway- (Figure 1j) and cholesterol pathway-associated genes 311 
(Figure 1k). Significant genes identified from multivariate O-PLS regression models were 312 
further validated by partial Spearman’s correlation adjusting for age, BMI, sex, and 313 
country (Figure 1l,m). Remarkably, the expression of all Notch receptors (NOTCH1, 314 
NOTCH2, NOTCH2NL, NOTCH3, NOTCH4) and Jagged ligands (JAG1, JAG2), but not 315 
that of delta-like ligands, was negatively associated with the APOA1BP expression 316 
15 
 
(Figure 1l). The expression of APOA1BP was also associated with the expression of 317 
cholesterol transporters such as ABCA1 and SCARB1 (Figure 1m). Significant O-PLS 318 
models were also obtained for the associations between SREBF1 expression and genes 319 
from both Notch and cholesterol pathways (Supplementary Figure 2a,b). Notably, after 320 
partial Spearman’s validation (Supplementary Figure 2c,d), the SREBF1 expression was 321 
positively associated with NOTCH1 and ABCA1, which we had found to be negatively 322 
associated with APOAB1P. Contrary to SREBF1 results, we did not obtain a significant 323 
O-PLS between the expression of SREBF2 and Notch pathway genes (Q2Y=-0.21). 324 
Finally, Aan O-PLS regression model between cholesterol synthesis pathway genes and 325 
NOTCH2NL identified a negative association with APOA1BP, whereas ABCA1 had the 326 
strongest positive association (Supplementary Figure 2e,f). 327 
ASSOCIATIONS OF THE APOA1BP-SREBF-NOTCH AXIS WITH THE SERUM 328 
METABOLIC PROFILES 329 
O-PLS regression models were built to identify serum metabolites associated with the 330 
expression of APOA1BP, SREBF1, and SREBF2. A significant O-PLS model was 331 
obtained for the prediction of APOA1BP expression levels from the serum metabolic 332 
profile (Figure 2a). Significant identified metabolites (Figure 2b) were further validated 333 
by partial Spearman’s correlation (Figure 2c). We identified asparagine, glycerol, 334 
histidine, glycine, choline and citrate as positively associated with the expression of 335 
APOA1BP, whereas glyceryl of lipids and very low level cholesterol in VLDL were 336 
associated negatively. Metabolites associated positively with APOA1BP had negative 337 
associations with atherosclerosis measures, particularly LmCCA (Figure 2g-i). We also 338 
found a borderline significant negative (r = -0.22, P = 0.051) association between the 339 
expression of APOA1BP and the inflammatory marker NAG. Metabolome-wide 340 
association studies (MWAS) were also performed for the liver expression of SREBF1 and 341 
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SREBF2 using O-PLS multivariate regressions (Figure 2d,e and Supplementary Figure 342 
3a) confirmed by partial Spearman’s correlation (Figure 2 f and Supplementary Figure 343 
3b). As expected, the expression of both genes was positively associated with several 344 
lipids. They also had positive associations with inflammatory markers [N-345 
acetylglycoproteins (NAG)], branched-chain amino acids (BCAA) (valine, isoleucine) 346 
and related catabolites (α-ketoisovalerate), lactate and proline. Most of these metabolites 347 
had positive correlations with cIMT measures. In particular, BCAA had positive 348 
associations with RICAe (Figure 2j-l), whereas NAG and α-ketoisovalerate had positive 349 
associations with mCA (R=0.27, P=0.028; and R=0.33, P=0.006, respectively). 350 
 351 
ASSOCIATIONS OF HAEMATOPOIESIS AND LIPIDS WITH THE SERUM 352 
METABOLIC PROFILES 353 
O-PLS regression models were also constructed to reveal associations between those 354 
haematological and lipid parameters associated with the APOA1BP-SREBF-NOTCH axis 355 
and the serum metabolome. A significant model with a strong predictive ability (Figure 356 
3a) was obtained between the serum metabolic profile and the HDL-C levels. After 357 
validation of the multivariate-identified metabolites by partial Spearman correlation, 358 
metabolites associated with HDL-C were similar to those linked to APOA1BP and 359 
SREBF1 (Figure 3b). Hence, phosphocholine, choline, glycerol, and glycine, which 360 
correlated positively with the expression of APOA1BP, also had a positive correlation 361 
with HDL-C. Conversely, several lipids, inflammation-related metabolites (NAG), 362 
BCAA (valine, isoleucine) and lactate, which were positively associated with SREBF1, 363 
had a negative association with the circulating levels of HDL-C. Notably, the expression 364 
of NOTCH2NL correlated negatively with the serum choline and phosphocholine levels 365 
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(Figure 3c,d) but positively with the BCAAs leucine and isoleucine (Figure 3e,f). It also 366 
had a trend towards a positive association with NAG (r = 0.20, P = 0.07). A significant 367 
O-PLS regression model was also obtained between the fasting serum TG levels and the 368 
serum metabolome (Figure 3g). Patients with higher TG concentrations had higher levels 369 
of several lipids, BCAAs and catabolites (isoleucine, α-ketoisovalerate), inflammation-370 
related metabolites (NAG), aspartate, proline, and acetone (Figure 3h). As expected, these 371 
results agree with those metabolites positively associated with SREBF1. Interestingly, 372 
several metabolites negatively associated with TG, including glycine, asparagine, 373 
phosphocholine, glycerol, and histidine, were found to be positively associated with the 374 
expression of APOA1BP. Finally, O-PLS regression models (Figure 3i) confirmed by 375 
partial Spearman’s correlation (Figure 3j) revealed that serum metabolites positively 376 
associated with the leukocyte counts were similar to those associated with the expression 377 
of SREBF1.  378 
 379 
Discussion 380 
Atherosclerosis and its progression is caused by lipid accumulation and local 381 
inflammation of blood vessels, and is the major underlying cause of CVD. High plasma 382 
concentrations of HDL have shown anti-atherogenic potential because HDL carries 383 
excess cholesterol away from cells. Importantly, human studies have shown that HDL 384 
cholesterol efflux capacity, a metric of HDL function that characterizes a key step in RCT, 385 
may be athero-protective [1,3]. Recent in vitro and animal studies have shown that AIBP 386 
may protect against atherosclerosis [5–8]. Here, we provided evidence for the first time, 387 
to our knowledge, in humans of an inverse association between the expression of 388 
APOA1BP and atherosclerosis measures. 389 
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In vitro studies have demonstrated a role of AIBP in promoting cholesterol efflux from 390 
human umbilical vein endothelial cells to HDL and THP-1-derived macrophages, thereby 391 
reducing lipid accumulation [5,6]. Mechanistically, AIBP enhances cholesterol efflux and 392 
RCT by preventing ABCA1 protein degradation through facilitating its binding to 393 
APOA1 on the cell membrane, thereby increasing ABCA1 levels [5]. Growing evidence 394 
suggests that ABCA1 protects from atherosclerosis by exporting excess cholesterol from 395 
cells to poorly lipidated APOA1, which is essential for the biogenesis of nascent HDL in 396 
hepatocytes [23]. Recent animals studies have also highlighted the protection of AIBP 397 
against atherosclerosis [7,8]. Hence, Apoe-/- mice with established atherosclerosis and 398 
treated with recombinant adeno-associated virus (rAAV) to overexpress AIBP showed 399 
reduction of atherosclerotic plaque size and inflammation but increased circulating HDL 400 
levels and RCT to the liver [8]. In the latter model, AIBP was overexpressed in the aorta 401 
and peritoneal macrophages, but mainly in the liver. The striking increase in ABCA1 402 
protein levels in the aortas and peritoneal macrophages of AIBP-treated mice suggests 403 
again that the effects of AIBP are mediated through ABCA1. In another animal study, 404 
Apoa1bp-/-Ldlr-/- mice fed a high-fat, high-cholesterol diet had exacerbated weight gain, 405 
liver steatosis, hyperlipidaemia and atherosclerosis compared to Ldlr-/- mice [7]. In 406 
addition, AAV-mediated overexpression of AIBP in Ldlr-/- mice protected against weight 407 
gain, plasma lipid increase and atherosclerosis compared to controls.  408 
In agreement with these results, we found negative associations between APOA1BP 409 
expression levels and measures of cIMT. Conversely, we found a negative association 410 
between the expression levels of APOA1BP and ABCA1. It is possible that in patients 411 
with reduced hepatic APOA1BP expression, there is a compensatory response in the 412 
expression of ABCA1 to increase cholesterol efflux in the liver. In addition, although 413 
treatment with AIBP increased ABCA1 protein levels in macrophages and Apoe-/- mice, 414 
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it did not alter the ABCA1 mRNA expression [5,8]. In fact, ABCA1 protein levels and 415 
mRNA expression are usually discordant as ABCA1 protein levels are regulated by a 416 
diverse posttranscriptional mechanism [24]. In contrast to ABCA1, which is important 417 
for the generation of nascent HDL, scavenger receptor class B member 1 (SR-BI) is a 418 
receptor for mature HDL and mediates selective uptake of HDL cholesteryl esters into 419 
the liver as the final step in RCT [25]. Consistently, we found a significant association 420 
between APOA1BP and SCARB1, which encodes the SR-BI protein, which was opposite 421 
to the APOA1BP-ABCA1 correlation.  422 
In addition to the ABCA1 transporter pathway, the VLDL-APOB secretion pathway has 423 
been proposed as the major pathway for the secretion of cholesterol from hepatocytes 424 
together with TG into plasma [26]. Interestingly, the VLDL secretion pathway is 425 
modulated by SREBP1c [27], encoded by SREBF1, which we found strongly positively 426 
associated with atherosclerosis. Specifically, SREBF1 correlated with cIMT measures in 427 
all segments of the left carotid artery, which is in agreement the higher vulnerability of 428 
the left carotid artery to atherosclerosis [28,29]. . Hepatic expression of SREBP1c is also 429 
increased in hepatic steatosis [30], which is consistent with our results. A recent study in 430 
zebrafish has shown that Aibp2-mediated HPSC expansion through the up-regulation of 431 
Srebf2 (but not Srebf1), which predominantly regulates cholesterol synthesis [14]. 432 
Although we mainly found SREBF1 associated with cIMT rather than SREBF2, it is worth 433 
noting that SREBF1 is transcribed into two variants: SREBP-1c, which solely regulates 434 
lipid synthesis, and SREBP-1a, which controls both cholesterol and lipid synthesis. AIBP  435 
also seem to modulate Notch signalling in mice and zebrafish [13,14]. In agreement with 436 
these results, we found strong associations between the expression of APOA1BP and the 437 
expression of all Notch signalling receptors and jagged ligands, but not with delta-like 438 
ligands. Interestingly, jagged and delta-like ligands have shown opposite effects on 439 
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angiogenesis and regulation of T cells [31,32]. Consistent with a higher susceptibility of 440 
the left carotid artery, wAlthough wee also found that NOTCH1 and NOTCH4 were 441 
positively associated with left cIMT measuresatherosclerosis. Despite these associations, 442 
, it is particularly noticeable that the expression of human-specific gene NOTCH2NL had 443 
the strongest associations with atherosclerotic measures. Interestingly, among all genes 444 
involved in cholesterol metabolism, NOTCH2NL had the strongest positive association 445 
with ABCA1, suggesting again a potential upregulation of ABCA1 expression to increase 446 
cholesterol efflux in patients with cIMT. Little is known about NOTCH2NL, but it has 447 
recently stood out for its ability to enhance Notch signalling and expand human cortical 448 
progenitor cells [33,34]. Consistent with this link between cholesterol metabolism and 449 
haematopoiesis, we found significant associations among the expression of APOA1BP, 450 
SREBF1 and NOTCH2NL, and haematology and lipid parameters. 451 
We found that the expression of transcripts APOA1BP, SREBF1, SREBF2 and 452 
NOTCH2NL was associated with several plasma metabolites. APOA1BP had positive 453 
correlations with three amino acids (asparagine, histidine, glycine), glycerol, choline and 454 
citrate. These amino acids were also associated positively with circulating HDL-C levels, 455 
but negatively with TG and WBC counts. Glycine, histidine and asparagine were also 456 
negatively associated with cIMT measures. Of note, among 35 plasma metabolites 457 
quantified in 1049 individuals without coronary artery disease (CAD) and diabetes, 458 
histidine was most strongly associated with lower risk for incident CAD, followed by 459 
asparagine [35]. Low circulating levels of glycine have also been causally associated with 460 
higher incidence of coronary heart disease [36].  461 
APOA1BP expression also had a positive association with choline. Remarkably, both 462 
choline and phosphocholine levels had very strong positive associations with HDL-C but 463 
correlated negatively with the expression of NOTCH2NL. There is evidence suggesting a 464 
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connection between choline and HDL metabolism. Hence, phosphatidylcholine is the 465 
major phospholipid component of all plasma lipoproteins and the biosynthesis of 466 
phosphatidylcholine in the liver is critical for the synthesis and secretion of HDL and 467 
VLDL [37]. Interestingly, APOA1BP correlated negatively with the expression of liver 468 
enzymes involved in the synthesis of phosphatidylcholine from choline and 469 
phosphocholine, suggesting an up-regulation of the synthesis of phosphatidylcholine in 470 
patients with lower APOA1BP to increase assembly and clearance of lipoproteins. Due to 471 
the role of lecithin–cholesterol acyltransferase (LCAT) in the formation of HDL and 472 
RCT, we also assessed the relation between the expression levels of APOA1BP and LCAT 473 
and found a positive association (R=0.27, P=0.01). Interestingly, although studies in the 474 
general population gave inconsistent results, patients with LCAT deficiency have shown 475 
a significant increase in the incidence of CVD [38]. Despite the associations with 476 
APOA1BP and HDL, neither choline nor phosphocholine had associations with measures 477 
of atherosclerosis. Previous studies have shown inconsistent associations between 478 
circulating choline and phosphocholine levels and cardiovascular events. Both 479 
metabolites were positively associated with the risk of CVD and stroke after 4.8 years of 480 
follow-up in participants at high cardiovascular risk within the PREDIMED study, but no 481 
associations were found between 1-year changes in these metabolites and the incidence 482 
of CVD [39]. Similarly, higher plasma choline levels were associated with increased risk 483 
of major cardiac events after 3 years of follow-up in patients undergoing elective 484 
diagnostic coronary angiography, but they did not predict risk when trimethylamine N-485 
oxide, a choline metabolite, was added to the model [40]. In cross-section studies higher 486 
plasma choline concentrations have been associated with an unfavourable 487 
cardiometabolic risk factor profile, including lower HDL levels [41,42]. However, it is 488 
worth noting that plasma choline levels do not reflect choline status because disturbances 489 
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in circulating choline arise early in disease development [43,44] and circulating levels 490 
may depend on lipid overload. In this sense, plasma choline metabolites differed between 491 
normal and overweight men [45]. In addition, both low and high plasma concentrations 492 
may be associated with adverse effects [46]. 493 
As expected, the expression levels of SREBF1 and SREBF2 had positive associations with 494 
several lipids. These genes also correlated positively with circulating levels of BCAA and 495 
catabolites, NAG and lactate. Except for lactate, we found that these metabolites were all 496 
positively associated with measure of cIMT. Several cross-section and prospective cohort 497 
studies revealed positive associations of BCAA with major metabolic disorders [47] and 498 
recently they have also been positively associated with risk factors of CAD, in particular 499 
cIMT [48]. Interestingly, we also found a positive correlation between the expression 500 
levels of NOTCH2NL and BCAA. In line with atherosclerosis being a chronic 501 
inflammatory disorder, we found a consistent association between NAG, a novel marker 502 
of chronic inflammation [22], and cIMT measures. Consistently, we found that NAG 503 
levels were the strongest predictors of WBC counts, which also had positive associations 504 
with BCAA. Supporting the role of the APOA1BP-SREBF-NOTCH axis and 505 
inflammation in atherosclerosis, we also found that NAG levels were negatively 506 
associated with the expression of APOA1BP, but positively with that of SREBF1, 507 
SREBF2, and NOTCH2NL. Finally, most of the metabolites associated with SREBF1 and 508 
SREBF2 had similar associations with TG, but opposite to those of HDL. 509 
The main limitation of our study is its cross-sectional nature. Therefore, we cannot infer 510 
cause-effect relationships. Second, the results cannot be extrapolated to the general 511 
population, as subjects in the current study were morbidly obese. In addition, we did not 512 
measure AIBP protein levels. The strengths of the present work include the use of two 513 
independent well-characterized cohorts, which allowed the control for potential 514 
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confounders, with comprehensive metabolomic, transcriptomic, liver biopsy and cIMT 515 
data. 516 
In conclusion, our findings demonstrate, for the first time, an atheroprotective association 517 
between the expression levels of APOA1BP and atherosclerosis in humans. We have also 518 
shown a connection between APO1ABP, Notch signalling and inflammation with 519 
atherosclerosis.  520 
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Figure Legends 691 
Figure 1. Associations of expression levels of APOA1BP, SREBFs, and NOTCHs gens 692 
with cIMT, steatosis, haematology and lipid measures and cholesterol and notch 693 
pathway genes. a) Heatmap displaying the partial Spearman’s correlation coefficients 694 
(adjusted for age, BMI, sex, and cohort) between genes and cIMT measures. *p<0.05, 695 
**p<0.01, ***p<0.001. b) Association of expression levels of SREBF1 with the steatosis 696 
degree (ANCOVA and Tukey-kramer tests). c) Cholesterol metabolism pathway genes 697 
significantly associated with mean CCA based on partial Spearman’s correlation adjusted 698 
for age, BMI, sex, and cohort. d-i) Scatter plots between expression levels of selected 699 
genes and haematological and lipid parameters. Partial Spearman’s correlation and 700 
significance values adjusted for age, BMI, sex, and cohort are shown. j-k)  Permutation 701 
test for the goodness-of-fit (R2Y) and goodness of prediction (Q2Y) obtained from the O-702 
PLS models between the expression levels of APOA1BP and the expression levels of 703 
genes involved in the Notch signalling and cholesterol pathways, respectively. l-m)  704 
Significant Notch and cholesterol pathway genes associated with APOA1BP after further 705 
validation of the O-PLS identified genes by partial Spearman’s correlation adjusting for 706 
age, sex, BMI, and country. 707 
Figure 2. Associations of metabolomics data with the expression levels of APOA1BP, 708 
SREBF1,and cIMT measures. a) Permutation test for the goodness-of-fit (R2Y) and 709 
goodness of prediction (Q2Y) obtained from the O-PLS models between the expression 710 
levels of APOA1BP and the serum metabolome. b) Significant serum metabolites 711 
obtained from the O-PLS model. Statistically significant metabolites are coloured in red 712 
if positively associated with APOA1BP and blue if negatively associated. c) Metabolites 713 
associated with APOA1BP after further validation of the O-PLS identified metabolites by 714 
partial Spearman’s correlation adjusting for age, sex, BMI, and country. d) Permutation 715 
33 
 
test for the goodness-of-fit (R2Y) and goodness of prediction (Q2Y) obtained from the O-716 
PLS models between the expression levels of SREBF1 and the serum metabolome. e) 717 
Significant serum metabolites obtained from the O-PLS model. Statistically significant 718 
metabolites are coloured in red if positively associated with SREBF1 and blue if 719 
negatively associated. f) Metabolites associated with SREBF1 after further validation of 720 
the O-PLS identified metabolites by partial Spearman’s correlation adjusting for age, sex, 721 
BMI, and country. g-l) Scatter plots between selected metabolites and cIMT measures. 722 
Partial Spearman’s correlation and significance values adjusted for age, BMI, sex, and 723 
cohort are shown. 724 
Figure 3. Associations of metabolomics data with the lipid parameters, WBC, and 725 
NOTCH2NL expression levels. a) Permutation test for the goodness-of-fit (R2Y) and 726 
goodness of prediction (Q2Y) obtained from the O-PLS models between the expression 727 
levels of HDL-C and the serum metabolome. b) Metabolites associated with HDL-C after 728 
further validation of the O-PLS identified metabolites by partial Spearman’s correlation 729 
adjusting for age, sex, BMI, and country. c-f) Scatter plots between selected metabolites 730 
and NOTCH2NL expression levels. Partial Spearman’s correlation and significance 731 
values adjusted for age, BMI, sex, and cohort are shown. g) Permutation test for the 732 
goodness-of-fit (R2Y) and goodness of prediction (Q2Y) obtained from the O-PLS models 733 
between the expression levels of TG and the serum metabolome. h) Metabolites 734 
associated with TG after further validation of the O-PLS identified metabolites by partial 735 
Spearman’s correlation adjusting for age, sex, BMI, and country. i) Permutation test for 736 
the goodness-of-fit (R2Y) and goodness of prediction (Q2Y) obtained from the O-PLS 737 
models between the expression levels of WBC and the serum metabolome. j) Metabolites 738 
associated with WBC after further validation of the O-PLS identified metabolites by 739 
partial Spearman’s correlation adjusting for age, sex, BMI, and country. 740 
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Supplementary Figure 1. a) Cholesterol metabolism pathway genes significantly 741 
associated with mean CA based on partial Spearman’s correlation adjusted for age, BMI, 742 
sex, and cohort. b) Heatmap displaying the partial Spearman’s correlations (adjusted for 743 
age, BMI, sex, and cohort) between cIMT measures and inflammation measured by NMR 744 
plasma levels of N-acetylglycoproteins (NAG). c) Heatmap displaying the partial 745 
Spearman’s correlation coefficients (adjusted for age, BMI, sex, and cohort) between 746 
genes and haematological parameters. d) Heatmap displaying the partial Spearman’s 747 
correlation coefficients (adjusted for age, BMI, sex, and cohort) between haematological 748 
parameters and cIMT measures. 749 
Supplementary Figure 2. a,b) Permutation test for the goodness-of-fit (R2Y) and 750 
goodness of prediction (Q2Y) obtained from the O-PLS models between the expression 751 
levels of SREBF1 and the expression levels of genes involved in Notch signalling and 752 
cholesterol synthesis pathways, respectively. c,d) Significant Notch signalling and  753 
cholesterol pathway genes associated with SREBF1 after further validation of the O-PLS 754 
identified genes by partial Spearman’s correlation adjusting for age, sex, BMI, and 755 
country, respectively. ea) Permutation test for the goodness-of-fit (R2Y) and goodness of 756 
prediction (Q2Y) obtained from the O-PLS models between the expression levels of 757 
NOTCH2NL and the expression levels of genes involved in cholesterol synthesis 758 
pathway. fb)  Significant cholesterol pathway genes associated with NOTCH2NL after 759 
further validation of the O-PLS identified genes by partial Spearman’s correlation 760 
adjusting for age, sex, BMI, and country. 761 
Supplementary Figure 3. a) Permutation test for the goodness-of-fit (R2Y) and goodness 762 
of prediction (Q2Y) obtained from the O-PLS models between the expression levels of 763 
SREBF2 and the serum metabolome. b) Significant serum metabolites obtained from the 764 
O-PLS model. Statistically significant metabolites are coloured in red if positively 765 
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associated with SREBF2 and blue if negatively associated. c) Metabolites associated with 766 
SREBF2 after further validation of the O-PLS identified metabolites by partial 767 




Table 1. Baseline characteristics of participants. 770 
Variables All (n=78) 
Age (years) 42.4 ± 1.16 
BMI (kg/m2) 46.2 (42.4-51.1) 
Waist circumference (cm) 127.0 (119.5-138.0) 
Sex (women, %) 79.2 
SBP (mmHg) 134.0 (122.5-144.0) 
DBP (mmHg) 81.0 (75.0-90.0) 
Biochemistry  
Glucose (mg/dL) 95.0 (88.5-101.5) 
HOMA-IR 4.50 (2.95-6.90) 
Triglycerides (mg/dL) 112.0 (82.0-143.5) 
Total cholesterol (mg/dL) 197.5 ± 4.6 
LDL cholesterol (mg/dL) 131.0 ± 4.0 
HDL cholesterol (mg/dL) 45.0 (40.0-51.2) 
Haematology  
Eosinophils 150.0 (100.0-200.0) 
Neutrophils 4810 (3665-5795) 
Lymphocytes 2360 ± 86.9 
Monocytes 500 (420-600) 
Total WBC 7350 (6385-9030) 
RBC 4.66 (4.46-4.91) 
Liver  
HsCRP 0.88 (0.47-1.39) 
AST 19.0 (15.0-28.0) 
ALT 30.0 (22.0-43.5) 
Steatosis grade (%):  
Grade 0 15.6 
Grade 1 33.8 
Grade 2 24.7 
Grade 3 26.0 
Atherosclerosis  
RproCCAi 0.70 (0.60-0.80) 
RproCCAe 0.70 (0.60-0.80) 
RpreCCAi 0.79 ± 0.03 
RpreCCAe 0.72 (0.60-0.80) 
RICAi 0.70 (0.60-0.90) 
RICAe 0.70 (0.54-0.85) 
mRCCA 0.73 ± 0.02 
mRICA 0.71 ± 0.02 
LproCCAi 0.70 (0.60-0.85) 
LproCCAe 0.69 (0.60-0.80) 
LpreCCAi 0.80 (0.70-1.0) 
LpreCCAe 0.84 ± 0.03 
LICAi 0.77 (0.57-0.90) 
LICAe 0.70 (0.60-0.87) 
mLCCA 0.76 ± 0.02 
mLICA 0.73 ± 0.03 
mCCA 0.74 ± 0.02 
mCA 0.73 ± 0.02 
Values are expressed as means ± SEM for normally distributed variables and median [IQR] for non-normally 771 
distributed variables. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HsCRP, high sensitivity 772 
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C-reactive protein; e, external; i, internal; ICA, internal carotid artery; L, left; m, mean; preCCA, pre bifurcation 773 
common carotid artery; proCCA, proximal segment common carotid artery; R, right; RBC, red blood cells; WBC, 774 
white blood cells. 775 
 
 
Reference: YCLNU-D-19-01600 1 
 2 
Title: The APOA1BP-SREBF-NOTCH axis is associated with reduced atherosclerosis 3 
risk 4 
General comments to the reviewers 5 
We greatly appreciate all the comments and suggestions made by the reviewers, the 6 
responses to which strengthen our manuscript. We have revised and modified the 7 
manuscript according to these suggestions, as detailed below.  8 
 9 
Responses to Reviewer 1 10 
 11 
Reviewer #1: The manuscript titled "The APOA1B-SREBF-NOTCH axis is associated with 12 
reduced atherosclerosis risk," is interesting and clearly written. It has a novelty because 13 
the authors tried to elucidate the association between APOA1B-SREBF-NOTCH axis and 14 
atherosclerosis in humans. However, the reviewer has several concerns regarding this 15 
article. Specific comments are as follows.  16 
 17 
Major points: 18 
 19 
1.      The authors demonstrated the possible relations between APOA1B and SREBF, and 20 
between APOA1B and NOTCH. However, the reviewer cannot find the data showing the 21 
relation between SREBF-NOTCH. Since the authors claim "the APOA1B-SREBF-NOTCH 22 
axis", they should show clearly the relation between SREBF-NOTCH. We thank the 23 
reviewer for this comment and we agree with him that we had not shown a clear 24 
evidence for the relation between SREBF and NOTCH signalling. Therefore, similar 25 
to what we did for the associations between APOA1BP expression and Notch and 26 
cholesterol pathway associated genes, we built O-PLS models between the expression 27 
of SREBF1 and Notch and cholesterol genes, respectively. In both cases, we obtained 28 




pathways. Both models were further validated by partial Spearman’s correlation 30 
adjusting for age, sex, BMI, and country. Interestingly, the expression of SREBF1 31 
was positively associated with both NOTCH1 and ABCA1 expression, which we had 32 
found negatively associated with APOA1BP. In the case of SREBF2, however, we did 33 
not find significant associations with the Notch pathway genes. We have added all 34 
these results in the results section and we have created a new Supplementary Figure 35 
2. 36 
 37 
2.      In this study, the authors investigate morbidly obese population only, however, the 38 
title does not imply this specific population. The reviewer feels this could be misleading for 39 
the readers. We agree with the reviewer that the title lacks information about the 40 
study population and it can be misleading. We have added this information in the 41 
title and now it reads as: “The APOA1BP-SREBF-NOTCH axis is associated with 42 
reduced atherosclerosis risk in morbidly obese patients”. 43 
 44 
 45 
Minor points: 46 
 47 
1.      The O-PLS regression model figures are difficult to understand because those figures 48 
do not have adequate variables information. Please refer to figure 1j-k, 2a-b, 2d-e, 3a, 3g, 49 
3i, Supplemental figure 2a and Supplemental figures 3a-b. It would be easier to 50 
understand if these figures contain adequate information regarding the variables. We 51 
agree with the reviewer that the figures are no straightforwardly understandable 52 
without reading the figure legends. Following reviewer’s suggestion, we have added 53 
in each figure the variables X and Y involved in the corresponding model.  54 
 55 
2.      The reviewer found mistyping which is mentioned below: 56 
Page 13, line 280, "RproCAAi" should be "RproCCAi". Corrected 57 




Responses to Reviewer 2 60 
 61 
Reviewer #2: Mayneris-Perxachs, et al. investigated correlation between gene expression 62 
in the liver (e.g., APOA1BP, SREBF, and Notch) and carotid atherosclerosis in morbidly 63 
obese patients. The authors employed sophisticated methods such as metabolomics 64 
analyses and transcriptomic analyses, and suggested "APOA1BP-SREBF-NOTCH axis 65 
signaling pathway" and its association with atherosclerosis. 66 
This reviewer has following comments to this study. 67 
1.      The mechanisms by which APOA1BP-SREBF-NOTCH axis signaling pathway affect 68 
atherogenesis is not clear. How the difference in gene expression in the liver links with the 69 
carotid artery atherosclerosis? 70 
Recent evidence suggests that cholesterol pathways link hematopoiesis with 71 
atherosclerosis, with and interesting role for the AIBP-SREBP-NOTCH axis. The 72 
bone marrow is the main site of haematopoiesis in adults. However, the liver is the 73 
main site in prenatal development and some studies have provided evidence that it is 74 
still active in adults. Therefore, we hypothesized that the gene expression in the liver 75 
could be related to cholesterol metabolism and atherosclerosis. Thus, our aim was to 76 
show for the first time in humans an association of the APOA1BP-SREBF-NOTCH 77 
axis with atherosclerosis. We have to take into account that we have analysed cross-78 
sectional data. Therefore, we cannot infer causality or describe mechanisms, but just 79 
associations. In zebrafish, increased cholesterol efflux mediated by Aibp2 has shown 80 
to activate Srebp2, which in turn upregulated Notch resulting in an expansion of 81 
hematopoietic stem and progenitor cells (HPSC) in the bone marrow. In human 82 
subjects with hypercholesterolemia (the driving force for atheroscleroris) they found 83 
that the number of HPSC are elevated and SREBP and NOTCH are upregulated in 84 
HPSC isolated from these subjects. Here, we also found positive associations between 85 
SREBF1, SREBF2 and NOTCH2NL expression and atherosclerosis parameters and 86 
blood cells, whereas APOA1BP had opposite associations. We also found associations 87 
among APOA1BP, Notch pathway genes, and cholesterol pathway genes. However, 88 
we had not reported associations between SREBF and Notch pathway and cholesterol 89 
 
 
pathway genes. We have thus analysed this relationship by O-PLS modelling and 90 
similar to APOA1BP we have found significant models between SREBF1 and Notch 91 
and cholesterol genes, respectively. We have added these results in the revised version 92 
of the manuscript. Therefore, lower APOAB1P expression is associated with higher 93 
expression of SREBF1 and NOTCH receptors, which in turn are associated with 94 
higher levels of blood cells and atherosclerosis measures. We have also found 95 
significant associations between several white blood cells and atherosclerosis 96 
measures. Although we had not reported these associations in the original 97 
manuscript, we have added them in supplementary Figure 1d. Thus, we found a clear 98 
association among the APOA1BP-SREBF-NOTCH axis, haematopoiesis and 99 
atherosclerosis.   100 
 101 
2.      Please explain the difference in the correlation between gene expression (e.g., 102 
APOA1BP, SREBF, and NOTCH) and parameters for atherosclerosis in left/right carotid 103 
arteries (Page13). 104 
APOA1BP was  negatively associated with measurements in both left and right 105 
carotid arteries. Interestingly, SREBF1 was mainly positively associated with all the 106 
measurements in the left carotid artery, which would be in agreement with recent 107 
evidence that the left carotid artery is more vulnerable to atherosclerosis than the 108 
right carotid artery [1,2]. This is also consistent with NOTCH1 and NOTCH4 109 
positively associated with atherosclerosis measures in the left carotid artery. We have 110 
added this information in the discussion. In the case of NOTCH2NL though, it 111 
correlated with measures of the right internal carotid artery, but the reason for this 112 
association would need further investigations.  113 
[1] Selwaness M, Van Den Bouwhuijsen Q, Van Onkelen RS, Hofman A, Franco OH, 114 
Van Der Lugt A, et al. Atherosclerotic plaque in the left carotid artery is more 115 
vulnerable than in the right. Stroke 2014;45:3226–30. 116 
doi:10.1161/STROKEAHA.114.005202. 117 
[2] Chou CL, Wu YJ, Hung CL, Liu CC, Wang S De, Wu TW, et al. Segment-specific 118 
prevalence of carotid artery plaque and stenosis in middle-aged adults and elders in 119 
 
 
Taiwan: A community-based study. J Formos Med Assoc 2019;118:64–71. 120 
doi:10.1016/j.jfma.2018.01.009. 121 
 122 
3.      How do "APOA1BP", "SREBF", and "NOTCH" interact each other? 123 
From O-PLS modelling and further validation by partial Spearman correlation 124 
(adjusting for age, BMI, sex, and country) we had found significant associations 125 
between the expression of APOA1BP and NOTCH pathway genes. We also showed 126 
that APOA1BP and SREBF1 had opposite associations with the almost the same 127 
atherosclerosis measures, particularly mLCCA, mCCA, and mCA. However, we had 128 
not shown a direct relationship between SREBF and NOTCH. Thus, similar to what 129 
we did for the associations between APOA1BP expression and Notch and cholesterol 130 
pathway associated genes, we built O-PLS models between the expression of SREBF1 131 
and Notch and cholesterol genes, respectively. In both cases, we obtained significant 132 
models (P<0.001) associating SREBF1 with Notch and cholesterol pathways. Both 133 
models were further validated by partial Spearman’s correlation. Interestingly, the 134 
expression of SREBF1 was positively associated with both NOTCH1 and ABCA1 135 
expression, which we had found negatively associated with APOA1BP. In the case of 136 
SREBF2, however, we did not find significant associations with the Notch pathway 137 
genes. We have added all these results in the results section and we have created a 138 
new Supplementary Figure 2. Therefore, we have found a clear relationship between 139 
APOAB1P, SREBF, and NOTCH, but due to the cross-sectional nature of our study 140 
we cannot infer causal mechanisms or the direction of the associations.  141 
 142 
4.      The authors only described about Jagged ligand related with Notch. A previous study 143 
demonstrated the inhibition of Dll4, a Notch ligand, reduced lipid accumulation in the 144 
liver (PNAS 2012;109:E1868-E1877.). 145 
Thanks for pointing this. In Figure 1l we only showed the significant associations that 146 
we obtained between APOA1BP and genes from the Notch pathway. However, the O-147 
PLS models were performed considering 79 genes involved in the Notch signalling 148 
pathway. Then, significant genes identified through O-PLS modeling were further 149 
 
 
validated by partial Spearman’s correlation. These 79 genes included both jagged 150 
and delta-like ligands, but we did not find significant associations between delta-like 151 
ligand and APOA1BP expression. We only found significant associations with jagged 152 
ligands. Because of this, we have not discussed delta-like ligands in the manuscript. 153 
To avoid confusions, we have added the number of genes that we considered to build 154 
the O-PLS models based on Notch signalling pathway associated genes and 155 
cholesterol pathway associated genes in the revised version of the manuscript. We 156 
have also added the names of these genes in the Supplementary Tables 1 and 2, 157 
respectively. 158 
 159 
On the other hand, in our liver samples, only DLL1, DLK1 (delta like non-canonical 160 
Notch ligand1), and DLK2 were expressed, but not DLL4. Considering Fukuda et al. 161 
results suggested by the reviewer, we have analysed the possible association between 162 
delta-like ligands and steatosis. Thus, we have performed partial Spearman’s 163 
correlation analysis between these delta ligands and the steatosis degree in our 164 
population. However, we have not found any significant association, although the 165 
expression of DLK1 had a trend towards a positive association with the degree of 166 
steatosis (r=0.21, p=0.076). We must also take into account that Fukuda et al. treated 167 
mice with anti-mouse Dll4 antibody, which inhibits Dll4 in all Dll4-expressing cells, 168 
not just the liver. Therefore, decreases in the accumulation of lipids in the liver after 169 
Dll4 Ab treatment could originate from blockage of Dll4 in other tissues. In fact, Dll4 170 
Ab treatment also reduced fat in epididymal and sub-cutaneous adipose tissues.  171 
 172 
5. Do the authors have data associated with inflammation directly? 173 
From multivariate analyses, we have found direct associations of SREBF1 and 174 
SREBF2 expression with N-acetylglycoproteins (NAG) measured by NMR. It is a 175 
composite biomarker of systemic inflammation that integrates the protein levels and 176 
glycosylation states of several of the most abundant acute phase proteins in serum. As 177 
a composite biomarker, NAG is a novel marker of systemic inflammation that may be 178 
a better reflection of systemic acute phase response than any other single 179 
 
 
glycoprotein component. For example, it has low intra-individual variability 180 
compared to hsCRP, which often exhibits high intra-individual variability, allowing a 181 
more stable measure of inflammation.  182 
 183 
We have now specifically analysed the correlation between NAG and APOA1BP and 184 
NOTCH receptors. We have found an almost significant association between NAG 185 
and APOA1BP (r=-0.22, p=0.051). We have also found a trend towards a positive 186 
association between NOTCH2NL and NAG (r=0.20, p=0.07), but no significant 187 
associations with the expression of the other Notch receptors. We have added these 188 
results in the results section. 189 
 190 
We have also realized that although in lines 491-493 we had commented that NAG 191 
was associated with cIMT measures, we had not reported the associations in the 192 
results section. Therefore, we have added a heatmap in Supplementary Figure 1b 193 
with the correlations between NAG and measures of atherosclerosis. As expected, 194 
several of these measures correlated positively with NAG.  195 
 196 
6. Can the authors show the correlation between gene expression (e.g., APOA1BP, 197 
SREBF, and NOTCH) and WBC population such as monocyte or lymphocytes? 198 
We have added a heatmap in Supplementary Figure 1c with the correlations of 199 
haematological parameters (total WBC, lymphocytes, monocytes, eosinophils, 200 
neutrophils, red blood cells, and platelets) with the expression APOAB1P, SREBF 201 
and NOTCH genes. 202 
 203 
7. Can the author apply the results of present study to general population? If not, the 204 
authors need to make this clear in the title of this paper. 205 
As our population consisted in morbidly obese patients, the results may not be 206 
generalizable to the general population. Following the reviewer’s suggestion we have 207 
modified the title and now it reads as: “The APOA1BP-SREBF-NOTCH axis is 208 
associated with reduced atherosclerosis risk in morbidly obese patients”. 209 
 
 
Comments to the Editor 210 
 211 
We have added Dr. Josep Puig as an author in the paper. He was the person 212 
responsible for the measurements of carotid intima-media thickness, but as he has 213 
moved to another area we had forgotten to add him as an author. We apologise for 214 
this mistake and any inconvenience it may have caused. 215 
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Supplementary Table 2. Notch signalling pathway associated genes considered in the present 
study. 
Genes 
ABCA1 
ABCG1 
ACADL 
ACAT2 
ALMS1 
APLP2 
APOA1 
APOA1BP 
APOA2 
APOA4 
APOA5 
APOB 
APOBEC2 
APOBEC3A 
APOBEC3B 
APOBEC3C 
APOBEC3D 
APOBEC3F 
APOBEC3G 
APOBEC3H 
APOBR 
APOC1 
APOC2 
APOC3 
APOC4 
APOE 
APOF 
APOH 
APOL1 
APOL2 
APOL3 
APOL4 
APOL5 
APOL6 
APOLD1 
ARHGEF10L 
ARV1 
CAT 
CLN6 
CYB5R1 
CYB5R3 
CYP51A1 
DHCR24 
DHCR7 
EBP 
EBPL 
EHD1 
EIF2A 
EIF2AK3 
ERLIN1 
ERLIN2 
FDFT1 
FDPS 
FDX1 
FECH 
HDLBP 
HMGCR 
HSD17B7 
INSIG1 
INSIG2 
IRAK1 
LBR 
LDLR 
LDLRAP1 
LIPA 
LIPE 
LMF1 
LMNA 
LRP5 
LRP6 
LSS 
MBTPS1 
MED13 
MVD 
MVK 
NCOR1 
NPC1 
NPC1L1 
NPC2 
NR1H2 
NR1H3 
NUS1 
OSBP 
PCTP 
PLSCR3 
PMVK 
POR 
PRKAA1 
PTCH1 
RALY 
RORA 
SC5DL 
SCAP 
SCARB1 
SCP2 
SEC14L2 
SEC24A 
SIRT1 
SOD1 
SQLE 
SREBF1 
SREBF2 
STARD4 
STARD5 
STX12 
TM7SF2 
TMEM97 
VPS4A 
XBP1 
 
